

B2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057474 A2

- (51) International Patent Classification⁷: C12P (74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (21) International Application Number: PCT/US02/01842 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 19 January 2002 (19.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/262,995 19 January 2001 (19.01.2001) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): OMNI-GENE BIOPRODUCTS INC. [US/US]; 763(d) Concord Avenue, Cambridge, MA 02138 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HERMANN, Theron [US/US]; 18 Chilhowie Drive, Kinnelon, NJ 07405 (US). PATTERSON, Thomas, A. [US/US]; 89 Church Street, Attleboro, MA 02760 (US). PERO, Janice, G. [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US). YOCUM, Roger, R. [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). BALDENIUS, Kai-Uwe [DE/DE]; Kneippstrasse 16, 67063 Ludwigshafen (DE). BECK, Christine [DE/DE]; Max-Joseph-Strasse 35, 68167 Mannheim (DE).
- Published:
- without international search report and to be republished upon receipt of that report
 - with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/057474 A2

(54) Title: PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

(57) Abstract: The present invention features improved methods for producing pantoate and pantothenate utilizing microorganisms having modified pantothenate biosynthetic enzyme activities. In particular, the invention features methods for reducing byproduct formation and increasing yields and purity of desired product. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

Related Applications

The present invention claims the benefit of prior-filed provisional Patent Application Serial No. 60/262,995, filed January 19, 2001 (pending). The present invention is also related to U.S. Patent Application Serial No. 09/667,569, filed September 21, 2000 (pending), which is a continuation-in-part of U.S. Patent Application Serial No. 09/400,494, filed September 21, 1999 (abandoned). U.S. Patent Application Serial No. 09/667,569 also claims the benefit of prior-filed provisional Patent Application Serial No. 60/210,072, filed June 7, 2000, provisional Patent Application Serial No. 60/221,836, filed July 28, 2000, and provisional Patent Application Serial No. 60/227,860, filed August 24, 2000. The entire content of each of the above-referenced applications is incorporated herein by this reference.

Background of the Invention

Pantothenate, also known as pantothenic acid or vitamin B5, is a member of the B complex of vitamins and is a nutritional requirement for mammals, including livestock and humans (*e.g.*, from food sources, as a water soluble vitamin supplement or as a feed additive). In cells, pantothenate is used primarily for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). These coenzymes function in the metabolism of acyl moieties which form thioesters with the sulfhydryl group of the 4'-phosphopantetheine portion of these molecules. These coenzymes are essential in all cells, participating in over 100 different intermediary reactions in cellular metabolism.

The conventional means of synthesizing pantothenate (in particular, the bioactive D isomer) is *via* chemical synthesis from bulk chemicals, a process which is hampered by excessive substrate cost as well as the requirement for optical resolution of racemic intermediates. Accordingly, researchers have recently looked to bacterial or microbial systems that produce enzymes useful in pantothenate biosynthesis processes (as bacteria are themselves capable of synthesizing pantothenate). In particular, bioconversion processes have been evaluated as a means of favoring production of preferred isomer of pantothenic acid. Moreover, methods of direct microbial synthesis have recently been examined as a means of facilitating D-pantothenate production.

There is still, however, significant need for improved pantothenate production processes, in particular, for microbial processes optimized to produce higher yields of desired product.

Summary of the Invention

The present invention relates to improved processes (*e.g.*, microbial syntheses) for the production of pantothenate. In particular, the present inventors have discovered that deregulation of the pantothenate biosynthetic pathway and/or

5 deregulation of the isoleucine-valine (*ilv*) pathway in microorganisms, in addition to producing significantly increased pantoate and/or pantothenate titers, results in the synthesis of an alternate product, namely [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA"), referred to interchangeably herein as "β-alanine 2-(*R*)-hydroxyisovalerate", "β-alanine

10 2-hydroxyisovalerate", "β-alanyl-α-hydroxyisovalerate" and/or "pantothenate". The pathway leading to HMBPA (referred to herein as the "HMBPA biosynthetic pathway") involves certain enzymes conventionally associated with pantothenate and/or isoleucine-valine (*ilv*) biosynthesis, which when overexpressed, are capable of additionally participating in the HMBPA biosynthetic pathway. In particular, the pathway includes

15 conversion of α-ketoisovalerate to [R]-2-hydroxyisovalerate (α-HIV), catalyzed by a reductase activity (*e.g.*, PanE1, PanE2 and/or IlvC activities), followed by condensation of α-HIV with β-alanine, catalyzed by PanC activity. As the alternative HMBPA biosynthetic pathway competes for key precursors of pantothenate biosynthesis, namely α-ketoisovalerate (α-KIV) and β-alanine, and also competes for enzymes conventionally

20 associated with pantothenate biosynthesis, it is desirable to decrease or eliminate HMBPA biosynthesis in order to effectively increase pantothenate biosynthesis.

Accordingly, in one aspect the present invention features a process for the production of a HMBPA-free pantothenate composition that includes culturing a microorganism having a deregulated pantothenate biosynthetic pathway under

25 conditions such that a HMBPA-free pantothenate composition is produced. In another aspect, the invention features a process for the production of a HMBPA-free pantothenate composition that involves culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, said microorganism having PanB activity regulated such that a HMBPA-free

30 pantothenate composition is produced. Yet another aspect of the invention features a process for the production of a HMBPA-free pantothenate composition that involves culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, the microorganism having PanE activity regulated such that a HMBPA-free pantothenate composition is produced.

35 In yet another aspect, the invention features a process for the production of a HMBPA-free pantothenate composition that involves culturing a microorganism having a

deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, the microorganism having *IlvC* activity regulated such that a HMBPA-free pantothenate composition is produced. In yet another aspect, the invention features a process for the production of a HMBPA-free pantothenate composition that involves culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, said microorganism having *PanB* and *PanE* activities regulated such that a HMBPA-free pantothenate composition is produced. In yet another aspect, the invention features a process for the production of a HMBPA-free pantothenate composition that involves culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, said microorganism having *PanB* and *IlvC* activities regulated such that a HMBPA-free pantothenate composition is produced. Compositions produced according to the above-described methodologies are also featured as are microorganisms utilized in said methodologies. Also featured are processes for the production of a selectively mixed pantothenate:HMBPA compositions.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 is a schematic representation of the pantothenate and isoleucine-valine (*ilv*) biosynthetic pathways. Pantothenate biosynthetic enzymes are depicted in bold and their corresponding genes indicated in italics. Isoleucine-valine (*ilv*) biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics.

Figure 2 is a schematic representation of the biosynthetic pathway leading to the formation [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") in *B. subtilis*.

Figure 3 is a schematic depiction of the structure of [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA").

Figure 4 is a HPLC chromatogram of a sample of medium from a 14 L fermentation of PA824.

Figure 5 is a mass spectrum depicting the relative monoisotopic mass of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid.

Figure 6 depicts an alignment of the C-terminal amino acids from known or suspected PanB proteins.

Figure 7 is a schematic representation of the construction of the plasmid pAN624.

5 Figure 8 is a schematic representation of the construction of the plasmid pAN620.

Figure 9 is a schematic representation of the construction of the plasmid pAN636.

10 Figure 10 is a schematic representation of the construction of the plasmid pAN637 which allows selection for single or multiple copies using chloramphenicol.

Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of an alternative biosynthetic pathway in recombinant microorganisms which utilizes certain
15 pantothenate and/or isoleucine-valine (*ilv*) biosynthetic enzymes and precursors to make a byproduct or side product called [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA"). In particular, it has been discovered that bacteria that have been engineered to have deregulated pantothenate biosynthetic and/or isoleucine-valine (*ilv*) biosynthetic pathways are capable of generating HMBPA from α -ketoisovalerate (α -
20 KIV), a key product of the isoleucine-valine (*ilv*) biosynthetic pathway and precursor of the pantothenate biosynthetic pathway. Production of HMBPA in bacteria utilizes at least the pantothenate biosynthetic enzymes ketopantoate reductase (the *panE* gene product), the *panE2* gene product and/or acetohydroxyisomeroreductase (the *ilvC* gene product) and results from the condensation of [R]-2-hydroxyisovaleric acid (α -HIV),
25 formed by reduction of α -KIV, and β -alanine, the latter reaction being catalyzed by the pantothenate biosynthetic enzyme pantothenate synthetase (the *panC* gene product). The substrates α -KIV and β -alanine can be utilized for both pantothenate production and HMBPA production, β -alanine being provided, for example, by feeding and/or increased aspartate- α -decarboxylate activity (the *panD* gene product).

30 In order to decrease or eliminate competition for pantothenate biosynthesis precursors and/or biosynthetic enzymes, it is desirable to selectively regulate certain enzymes such that production is shifted away from HMBPA and towards pantoate/pantothenate. Preferably, microorganisms having a deregulated pantothenate biosynthetic pathway and/or a deregulated isoleucine-valine (*ilv*)
35 biosynthetic pathway are further engineered such that PanB and/or PanE are selectively

regulated. Selective regulation of PanB and/or PanE includes an optimization of levels of these enzymes such that production flows towards pantoate/pantothenate.

In particular, the invention features methods of producing compositions having increased ratios of pantothenate to HMBPA, preferably HMBPA-free pantothenate compositions. As used herein, the phrase "HMBPA-free pantothenate composition" describes a composition including pantothenate which is free of HMBPA and/or substantially free of HMBPA such that said composition includes insignificant amounts of HMBPA (*i.e.*, if HMBPA is present, it is present at a sufficiently low level or concentration relative to the level or concentration of pantothenate such that the composition can be considered HMBPA-free for technological, scientific and/or industrial purposes). Preferably, an HMBPA-free pantothenate composition includes pantothenate and, if HMBPA is present, it is present at a ratio of 10:100 (*i.e.*, 10% HMBPA versus 90% pantothenate, for example, as determined by comparing the peak areas when a sample of product is analyzed by HPLC) or less. More preferably, an HMBPA-free pantothenate composition includes pantothenate and, if HMBPA is present, it is present at a ratio of 9:100 (*i.e.*, 9% HMBPA versus 91% pantothenate) or less. Even more preferably, a HMBPA-free pantothenate composition includes pantothenate and, if HMBPA is present, it is present at a ratio of 8:100 (*i.e.*, 8% HMBPA versus 92% pantothenate) or less, 7:100 (*i.e.*, 7% HMBPA versus 93% pantothenate) or less, 6:100 (*i.e.*, 6% HMBPA versus 94% pantothenate) or less or 5:100 (*i.e.*, 5% HMBPA versus 95% pantothenate) or less. Even more preferably, a HMBPA-free pantothenate composition includes pantothenate and, if HMBPA is present, it is present at a ratio of 0.5:100 (*i.e.*, 0.5% HMBPA versus 99.5% pantothenate) or less, 0.2:100 (*i.e.*, 0.2% HMBPA versus 99.8% pantothenate) or less or 0.1:100 (*i.e.*, 0.1% HMBPA versus 99.9% pantothenate) or less. Values and ranges included and/or intermediate of the values set forth herein are also intended to be within the scope of the present invention.

In one embodiment, the invention features a process for the production of a HMBPA-free pantothenate that includes culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions such that a HMBPA-free pantothenate composition is produced. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway involving pantothenate biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of pantothenate. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of pantothenate in

microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of pantothenate *in vitro*.

As used herein, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein) such that pantothenate production is enhanced (*e.g.*, as compared to pantothenate production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). The term "pantothenate" includes the free acid form of pantothenate, also referred to as "pantothenic acid" as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of pantothenate or pantothenic acid with a cation, for example, calcium, sodium, potassium, ammonium), also referred to as a "pantothenate salt". The term "pantothenate" also includes alcohol derivatives of pantothenate. Preferred pantothenate salts are calcium pantothenate or sodium pantothenate. A preferred alcohol derivative is pantothenol. Pantothenate salts and/or alcohols of the present invention include salts and/or alcohols prepared *via* conventional methods from the free acids described herein. In another embodiment, a pantothenate salt is synthesized directly by a microorganism of the present invention. A pantothenate salt of the present invention can likewise be converted to a free acid form of pantothenate or pantothenic acid by conventional methodology. Preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 1 g/L or greater. More preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 2 g/L or greater.

The term "pantothenate biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the pantothenate biosynthetic pathway. For example, synthesis of pantoate from α -ketoisovalerate (α -KIV) proceeds *via* the intermediate, ketopantoate. Formation of ketopantoate is catalyzed by the pantothenate biosynthetic enzyme PanB or ketopantoate hydroxymethyltransferase (the *panB* gene product). Formation of pantoate is catalyzed by the pantothenate biosynthetic enzyme PanE1 or ketopantoate reductase (the *panE1* gene product). Synthesis of β -alanine from aspartate is catalyzed by the pantothenate biosynthetic enzyme PanD or aspartate- α -decarboxylase (the *panD* gene product). Formation of pantothenate from pantoate and β -alanine (*e.g.*, condensation) is catalyzed by the pantothenate biosynthetic enzyme PanC or pantothenate synthetase (the *panC*

gene product). Pantothenate biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a
5 microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, deregulated such that pantothenate production is enhanced), said enzyme being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), PanE1 (or ketopantoate reductase). In another embodiment, the
10 invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least two pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), and PanE1 (or
15 ketopantoate reductase). In another embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least three pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or
20 aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least four pantothenate biosynthetic enzymes deregulated, for example, a microorganism having PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase),
25 PanD (or aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase) deregulated.

In another aspect, the invention features a process for the production of a HMBPA-free pantothenate that includes culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions such that a HMBPA-free
30 pantothenate composition is produced, the microorganism further having a deregulated isoleucine-valine biosynthetic pathway. The term "isoleucine-valine biosynthetic pathway" includes the biosynthetic pathway involving isoleucine-valine biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in
35 the formation or synthesis of conversion of pyruvate to valine or isoleucine. The term "isoleucine-valine biosynthetic pathway" includes the biosynthetic pathway leading to

the synthesis of valine or isoleucine in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of valine or isoleucine *in vitro*.

As used herein, a microorganism "having a deregulated isoleucine-valine (*ilv*) pathway" includes a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein) such that isoleucine and/or valine and/or the valine precursor, α -ketoisovalerate (α -KIV) production is enhanced (*e.g.*, as compared to isoleucine and/or valine and/or α -KIV production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). Figure 1 includes a schematic representation of the isoleucine-valine biosynthetic pathway. Isoleucine-valine biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics. The term "isoleucine-valine biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the isoleucine-valine biosynthetic pathway. According to Figure 1, synthesis of valine from pyruvate proceeds *via* the intermediates, acetolactate, α,β -dihydroxyisovalerate (α,β -DHIV) and α -ketoisovalerate (α -KIV). Formation of acetolactate from pyruvate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid synthetase (the *ilvBN* gene products, or alternatively, the *alsS* gene product). Formation of α,β -DHIV from acetolactate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid isomeroreductase (the *ilvC* gene product). Synthesis of α -KIV from α,β -DHIV is catalyzed by the isoleucine-valine biosynthetic enzyme dihydroxyacid dehydratase (the *ilvD* gene product). Moreover, valine and isoleucine can be interconverted with their respective α -keto compounds by branched chain amino acid transaminases. Isoleucine-valine biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, deregulated such that valine and/or isoleucine and/or α -KIV production is enhanced), said enzyme being selected, for example, from the group consisting of *IlvBN*, *AlsS* (or acetohydroxyacid synthetase), *IlvC* (or acetohydroxyacid isomeroreductase) and *IlvD* (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, said enzyme being selected, for example, from the group consisting of *IlvBN*, *AlsS* (or acetohydroxyacid synthetase), *IlvC* (or

acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the production of a HMBPA-free composition of pantothenate that includes culturing a microorganism having at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, for example, said
5 microorganism having IlvBN or AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase) deregulated.

As mentioned herein, enzymes of the pantothenate biosynthetic pathway and/or the isoleucine-valine (*ilv*) pathway have been discovered to have an alternative
10 activity in the synthesis of [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") or the [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway. The term "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway" includes the alternative biosynthetic pathway involving biosynthetic enzymes and compounds (*e.g.*,
15 substrates and the like) traditionally associated with the pantothenate biosynthetic pathway and/or isoleucine-valine (*ilv*) biosynthetic pathway utilized in the formation or synthesis of HMBPA. The term "HMBPA biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of HMBPA in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of HMBPA *in vitro*.

The term "HMBPA biosynthetic enzyme" includes any enzyme utilized
20 in the formation of a compound (*e.g.*, intermediate or product) of the HMBPA biosynthetic pathway. For example, synthesis of 2-hydroxyisovaleric acid (α -HIV) from α -ketoisovalerate (α -KIV) is catalyzed by the *panE1* or *panE2* gene product (PanE1 is alternatively referred to herein as ketopantoate reductase) and/or is catalyzed by the *ilvC*
25 gene product (alternatively referred to herein as acetohydroxyacid isomeroreductase). Formation of HMBPA from β -alanine and α -HIV is catalyzed by the *panC* gene product (alternatively referred to herein as pantothenate synthetase).

The term "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA")" includes the free acid form of HMBPA, also referred to as "[R]-3-(2-
30 hydroxy-3-methyl-butyrylamino)-propionate" as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate with a cation, for example, calcium, sodium, potassium, ammonium), also referred to as a "3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid salt" or "HMBPA salt". Preferred HMBPA salts are
35 calcium HMBPA or sodium HMBPA. HMBPA salts of the present invention include salts prepared *via* conventional methods from the free acids described herein. An

HMBPA salt of the present invention can likewise be converted to a free acid form of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate by conventional methodology.

Based at least in part on the discovery that overexpression or deregulation of the pantothenate biosynthetic pathway and/or isoleucine-valine (*ilv*) pathway can result in alternative production of HMBPA (as compared to desired pantothenate production), the present invention features processes for the production of HMBPA-free pantothenate that involve culturing microorganisms that not only have the pantothenate biosynthetic pathway and/or the isoleucine-valine (*ilv*) pathway deregulated, but that further have certain enzymes selectively regulated such that production of HMBPA-free pantothenate compositions is favored. As defined herein, the term “selectively regulated” includes selecting for regulation or targeting a particular enzyme or enzymes from the pantothenate biosynthetic pathway or the isoleucine-valine (*ilv*) pathway known to be involved in both pantothenate and HMBPA synthesis in a manner that favors pantothenate production over HMBPA production. Preferred enzymes selected or targeted for regulation include PanE1, PanE2, PanB and/or IlvC.

In one embodiment, Pan E1 is selectively regulated. For example, the present inventors have discovered that overexpression of PanE1 can catalyze HMBPA precursor formation, therefore selectively regulating the amount or activity (*e.g.*, to slightly decrease PanE1 levels or activity) can shift formation from HMBPA production to pantothenate production (*i.e.*, favor pantothenate production over HMBPA production). Moreover, it has been discovered that PanE2 favors HMBPA production. Accordingly, another embodiment, features deleting or regulating *panE2*.

Likewise, the present inventors have discovered that increasing PanB activity can shift formation from the alternative HMBPA biosynthetic pathway to the pantothenate biosynthetic pathway, therefore selectively regulating the amount or activity of PanB can favor pantothenate production over HMBPA production. In one embodiment, PanB activity is increased by overexpressing or deregulating the *panB* gene. In another embodiment, PanB activity is increased by expressing multiple copies of the *panB* gene. PanB activity can be increased by decreasing feedback inhibition of PanB. In particular, it has been discovered that PanB activity can be increased by regulating (*e.g.*, selectively regulating) pantothenate kinase, a key enzyme in the formation of Coenzyme A (CoA) from pantothenate (see *e.g.*, U.S. Patent Application Serial No. 09/09/667,569). Regulation of pantothenate kinase (*e.g.*, decreasing the

activity or level of pantothenate kinase) reduced the production of CoA, in turn reducing feedback inhibition of PanB as well as favoring pantothenate accumulation. In one embodiment, pantotheante kinase activity is decreased (and PanB activity is in turn increased) by deleting CoaA and downregulating CoaX activity (CoaA and CoaX are
 5 both capable of catalyzing the first step in CoA biosynthesis in certain microorganisms). In another embodiment, pantothenate kinase activity is decreased (and PanB activity is in turn increased) by deleting CoaX and downregulating CoaA. In yet another embodiment, pantotheante kinase activity is decreased (and PanB activity is in turn increased) by downregulating CoaA and CoaX activities.

10 Yet another aspect of the present invention features processes for the production of HMBPA-free pantothenate that include culturing microorganisms under culture conditions selected to favor pantothenate production over HMBPA production. In particular, it has been discovered that conditions including, but not limited to, reduced steady state glucose, increased steady state dissolved oxygen and/or excess serine favor
 15 pantothenate production over HMBPA production. The term "reduced steady state glucose" includes steady state glucose levels less or lower than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0.2-1.0 g/L steady state glucose. Accordingly, reduced steady state glucose levels
 20 preferably include levels of less than 0.2 g/L steady state glucose. The term "increased steady state dissolved oxygen" includes steady state dissolved oxygen levels increased or higher than those routinely utilized for culturing the microorganism in question and, for example, inversely correlates with reduced steady state glucose levels. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely
 25 done in the presence of about 10-30% dissolved oxygen. Accordingly, increased steady state dissolved oxygen can include levels of greater than 30% dissolved oxygen, preferably as great as 95% dissolved oxygen. The term "excess serine" includes serine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant
 30 Examples is routinely done in the presence of about 0-2.5 g/L serine. Accordingly, excess serine levels can include levels of greater than 2.5 g/L serine, preferably between about 2.5 and 20 g/L serine.

In yet another embodiment, HMBPA production is favored by increasing pantothenate and/or isoleucine-valine (*ilv*) biosynthetic pathway precursors and/or
 35 intermediates as defined herein (*e.g.*, culturing microorganisms in the presence of excess

β -alanine, valine and/or α -KIV) or, alternatively, culturing microorganisms capable of producing significant levels of β -alanine in the absence of a β -alanine feed (*i.e.*, β -alanine independent microorganisms, as described in U.S. Patent Application Serial No. 09/09/667,569).

5

Various aspects of the invention are described in further detail in the following subsections.

10 I. Targeting Genes Encoding Various Pantothenate and/or Isoleucine-Valine(*ilv*) and/or HMBPA Biosynthetic Enzymes

In one embodiment, the present invention features targeting or modifying various biosynthetic enzymes of the pantothenate and/or isoleucine-valine(*ilv*) and/or HMBPA biosynthetic pathways. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term "gene", as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), the overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences that encode a second or distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which

the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences).

Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

- 5 The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes).
- 10 Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

- A "gene having a mutation" or "mutant gene" as used herein, includes a
- 15 gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as
- 20 compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more
- 25 preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As
- 30 used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene.

35

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a "reduced activity" or "reduced enzymatic activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "reduced activity" or "reduced enzymatic activity" can also include an activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is a temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an "increased enzymatic activity" can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a "reduced enzymatic activity" is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an

altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or producing said mutant protein or polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue can
5 have an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding microorganism expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the
10 activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

15 It will also be appreciated by the skilled artisan that nucleic acid molecules, genes, protein or polypeptides for use in the instant invention can be derived from any microorganisms having a HMBPA biosynthetic pathway, an *ilv* biosynthetic pathway or a pantothenate biosynthetic pathway. Such nucleic acid molecules, genes, protein or polypeptides can be identified by the skilled artisan using known techniques
20 such as homology screening, sequence comparison and the like, and can be modified by the skilled artisan in such a way that expression or production of these nucleic acid molecules, genes, protein or polypeptides occurs in a recombinant microorganism (*e.g.*, by using appropriate promoters, ribosomal binding sites, expression or integration vectors, modifying the sequence of the genes such that the transcription is increased
25 (taking into account the preferable codon usage), etc., according to techniques described herein and those known in the art).

In one embodiment, the genes of the present invention are derived from a Gram positive microorganism organism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the
30 microorganism). The term "derived from" (*e.g.*, "derived from" a Gram positive microorganism) refers to a gene which is naturally found in the microorganism (*e.g.*, is naturally found in a Gram positive microorganism). In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium* (*e.g.*, *Corynebacterium*
35 *glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism is of

the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*,
 5 *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group
 10 consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term “derived from *Bacillus subtilis*” or “*Bacillus subtilis*-derived” includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are
 15 *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis* *coaX* genes, *serA* genes, *glyA* genes, *coaA* genes, *pan* genes and/or *ilv* genes.

In another embodiment, the genes of the present invention are derived from a Gram negative (excludes basic dye) microorganism. In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a
 20 genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism of the genus *Escherichia*. In an even more preferred embodiment, the genes of the present invention are derived from *Escherichia coli*. In another embodiment, the genes of the present
 25 invention are derived from *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g.,
 30 isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* pantothenate biosynthetic genes and/or isoleucine-valine (*ilv*) biosynthetic genes and/or HMBPA biosynthetic genes. The term “recombinant nucleic acid molecule” includes a nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide
 35 sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or

more nucleotides). Preferably, a recombinant nucleic acid molecule (*e.g.*, a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the gene of interest is linked to the regulatory
5 sequence(s) in a manner which allows for expression (*e.g.*, enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

10 The term "regulatory sequence" includes nucleic acid sequences which affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences (*i.e.*, genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it
15 appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences (*e.g.*, to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant
20 nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory
25 sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-
30 termination signals and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring
35 Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism

(*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (*e.g.*, a pantothenate biosynthetic enzyme, an isoleucine-valine biosynthetic enzyme and/or a HMBPA biosynthetic enzyme) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (*e.g.*, bacteriophage which infect *Bacillus*).

In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (*e.g.*, a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P*₁₅, *P*₂₆ or *P*_{veg}, having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCCTGTCCACCAACCAAACTGTGCTCAGT
 ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT
 CCACGCTGTGTAATAATTTTACAAAAGGTATTGACTTTCCCTACAGGGTGT
 GTAATAATTTAATTACAGGCGGGGGCAACCCCGCCTGT (SEQ ID NO:1),
 GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT
 GTTTTGTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGCA
 AAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAGC
 AGGACGC (SEQ ID NO:2), and
 GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC
 GTTGATATAATTTAAATTTTATTTGACAAAAATGGGCTCGTGTGTACAATA
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:3). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (*e.g.*, *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and *SPO2* promoters. Additional

preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *cos*, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6, λ -PR or λ -PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (*e.g.*, transcription terminator sequences). The term "terminator sequences" includes regulatory sequences that serve to terminate transcription of mRNA. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences that allow for detection of the vector containing said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that encode antibiotic resistance sequences or that overcome auxotrophic mutations, for example, *trpC*, drug markers, fluorescent markers, and/or colorimetric markers (*e.g.*, *lacZ*/ β -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence that gets transcribed into an artificial RBS. The term "artificial ribosome binding site (RBS)" includes a site within an mRNA molecule (*e.g.*, coded within DNA) to which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of interest, for example, the native *panB* RBS TAAACATGAGGAGGAGAAAACATG (SEQ ID NO:4) or the native *panD* RBS ATTCGAGAAATGGAGAGAATATAATATG (SEQ ID NO:5)). Preferably, nucleotides that differ are substituted such that they are identical to one or more nucleotides of an ideal RBS when optimally aligned for comparisons. Ideal RBSs include, but are not limited to, AGAAAGGAGGTGA (SEQ ID NO:6), TTAAGAAAGGAGGTGANNNNATG (SEQ ID NO:7), TTAGAAAGGAGGTGANNNNNATG (SEQ ID NO:8), AGAAAGGAGGTGANNNNNNATG (SEQ ID NO:9), and AGAAAGGAGGTGANNNNNNATG (SEQ ID NO:10). Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panB*, for example, of *B. subtilis panB*) include CCCTCTAGAAGGAGGAGAGAAAACATG (SEQ ID NO:11) and

CCCTCTAGAGGAGGAGAAAACATG (SEQ ID NO:12). Preferred artificial RBSs (e.g., RBSs for increasing the translation of *panD*, for example, of *B. subtilis panD*) include TTAGAAAGGAGGATTTAAATATG (SEQ ID NO:13), TTAGAAAGGAGGTTTAATTAATG (SEQ ID NO:14),
 5 TTAGAAAGGAGGTGATTTAAATG (SEQ ID NO:15), TTAGAAAGGAGGTGTTTAAAATG (SEQ ID NO:16), ATTCGAGAAAGGAGG TGAATATAATATG (SEQ ID NO:17), ATTCGAGAAAGGAGGTGAATAATAATG (SEQ ID NO:18), and ATTCGTAGAAAGGAGGTGAATTAATATG (SEQ ID NO:19).

The present invention further features vectors (e.g., recombinant vectors)
 10 that include nucleic acid molecules (e.g., genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (e.g., plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic
 15 acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the
 20 present invention includes sequences that enhance replication in bacteria (e.g., replication-enhancing sequences). In one embodiment, replication-enhancing sequences function in *E. coli*. In another embodiment, replication-enhancing sequences are derived from pBR322.

In yet another embodiment, a recombinant vector of the present invention
 25 includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (e.g., *Bacillus*). In one embodiment, the antibiotic resistance sequences are selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo* (neomycin resistance) sequences, *kan* (kanamycin resistance) sequences and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For
 30 example, *bpr*, *vpr*, or *amyE* sequences can be used as homology targets for
 35 recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice

of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

IV. Recombinant Microorganisms

5 The present invention further features microorganisms, *i.e.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as described herein. As used herein, the term "recombinant microorganism" includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an
10 altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

 In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (*e.g.*, a microorganism which retains basic dye,
15 for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another
20 preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for
25 example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

30 In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella*, *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In
35 an even more preferred embodiment, the recombinant microorganism is *Escherichia*

coli. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *S. cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated pantothenate biosynthesis pathway or enzyme, a
5 deregulated isoleucine-valine (*ilv*) biosynthetic pathway or enzyme and/or a modified HMBPA biosynthetic pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least
10 one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a
15 pathway (e.g., to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (e.g., two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon" (defined herein). Due to the coordinated
20 regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of each gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene
25 products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the
30 operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback
35 resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one pantothenate biosynthetic enzyme, at least one isoleucine-valine biosynthetic enzyme, and/or at least one HMBPA biosynthetic enzyme is overexpressed. The term "overexpressed" or "overexpression" includes
5 expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

10 Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a
15 particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited
20 to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that
25 expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a microorganism can be
30 cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

35

V. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid medium) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (*e.g.*, carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, growth promoters and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (*e.g.*, oxygen) to result in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (*e.g.*, tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (*e.g.*, through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature

which results in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably
5 between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a
10 preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a system in which the
15 composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the
20 exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired
25 product (*e.g.*, pantoate and/or pantothenate). A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired compound is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production
30 of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a compound (*e.g.*, pantoate and/or pantothenate). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a time sufficient to reach a suitable concentration of pantoate and/or
35 pantothenate or suitable ratio of pantoate and/or pantothenate:HMBPA). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment,

culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 10 g/L of compound are produced in about 36 hours, at least about 10 to 20 g/L compound are produced in about 48 hours, or at least about 20 to 30 g/L compound in about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 20 g/L of compound are produced in about 36 hours, at least about 20 to 30 g/L compound are produced in about 48 hours, or at least about 30 to 50 or 60 g/L compound in about 72 hours. In another embodiment, microorganisms are cultured under conditions such that a ratio of HMBPA:HMBPA+pantothenate of 0.1:100 or less is achieved (*i.e.*, 0.1% HMBPA versus 99.9% pantothenate, for example, as determined by comparing the peak areas when a sample of product is analyzed by HPLC), preferably such that a ratio of 0.2:100 or less is achieved (0.2% HMBPA versus 99.8% pantotheante), more preferably such that a ratio of 0.5:100 or less is achieved (0.5% HMBPA versus 99.5% pantotheante). In yet another embodiment, microorganisms are cultured under conditions such that a ratio of HMBPA:HMBPA+pantothenate of 1:100 or less is achieved (*i.e.*, 1% HMBPA versus 99% pantothenate, for example, as determined by comparing the peak areas when a sample of product is analyzed by HPLC), preferably such that a ratio of 2:100 or less is achieved (2% HMBPA versus 98% pantotheante), more preferably such that a ratio of 3:100 or less is achieved (3% HMBPA versus 97% pantotheante), more preferably at least 4:100 or less (4% HMBPA versus 96% pantotheante), 5:100 or less (5% HMBPA versus 95% pantotheante), 6:100 or less (6% HMBPA versus 94% pantotheante), 7:100 or less (7% HMBPA versus 93% pantotheante), 8:100 or less (8% HMBPA versus 92% pantotheante), 9:100 or less (9% HMBPA versus 91% pantotheante), or 10:100 or less (10% HMBPA versus 90% pantotheante).

The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, pantoate and/or pantothenate). The term "recovering" a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization,

recrystallization, pH adjustment, lyophilization and the like. For example, a compound can be recovered from culture media by first removing the microorganisms from the culture. Media are then passed through or over a cation exchange resin to remove cations and then through or over an anion exchange resin to remove inorganic anions and organic acids having stronger acidities than the compound of interest. The resulting compound can subsequently be converted to a salt (*e.g.*, a calcium salt) as described herein.

Preferably, a desired compound of the present invention is "extracted", "isolated" or "purified" such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

Preferably, a production method of the present invention results in production of the desired compound at a significantly high yield. The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which

is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 2 g/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 10 g/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 20 g/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 30 g/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 40 g/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 50 g/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, pantoate and/or pantothenate) is produced at a level greater than 60 g/L. The invention further features a production method for producing the desired compound that involves culturing a recombinant microorganism under conditions such that a sufficiently elevated level of compound is produced within a commercially desirable period of time.

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is aspartate. In another embodiment, the biosynthetic precursor or precursor is β -alanine. The amount of aspartate or β -alanine added is preferably an amount that results in a concentration in the culture medium sufficient to enhance

productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of pantoate and/or pantothenate). Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder).

- 5 Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time. The term "excess β -alanine" includes β -alanine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of
10 about 0-0.01 g/L β -alanine. Accordingly, excess β -alanine levels can include levels of about 0.01-1, preferably about 1-20 g/L.

- In yet another embodiment, the biosynthetic precursor is valine. In yet another embodiment, the biosynthetic precursor is α -ketoisovalerate. Preferably, valine or α -ketoisovalerate is added in an amount that results in a concentration in the medium
15 sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. The term "excess α -KIV" includes α -KIV levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L α -KIV. Accordingly, excess α -KIV levels can include
20 levels of about 0.01-1, preferably about 1-20 g/L α -KIV. The term "excess valine" includes valine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.5 g/L valine. Accordingly, excess valine levels can include levels of about 0.5-5 g/L,
25 preferably about 5-20 g/L valine. Biosynthetic precursors are also referred to herein as "supplemental biosynthetic substrates".

- Another aspect of the present invention includes biotransformation processes which feature the recombinant microorganisms described herein. The term "biotransformation process", also referred to herein as "bioconversion processes",
30 includes biological processes which results in the production (*e.g.*, transformation or conversion) of appropriate substrates and/or intermediate compounds into a desired product (*e.g.*, pantoate and/or pantothenate).

- The microorganism(s) and/or enzymes used in the biotransformation reactions are in a form allowing them to perform their intended function (*e.g.*, producing
35 a desired compound). The microorganisms can be whole cells, or can be only those portions of the cells necessary to obtain the desired end result. The microorganisms can

be suspended (e.g., in an appropriate solution such as buffered solutions or media), rinsed (e.g., rinsed free of media from culturing the microorganism), acetone-dried, immobilized (e.g., with polyacrylamide gel or k-carrageenan or on synthetic supports, for example, beads, matrices and the like), fixed, cross-linked or permeablized (e.g.,
5 have permeablized membranes and/or walls such that compounds, for example, substrates, intermediates or products can more easily pass through said membrane or wall).

10 VI. Processes for the Production of Selectively Mixed Compositions of Pantothenate and HMBPA

The present invention further features processes and microorganisms for the production of selectively mixed compositions of pantothenate and HMBPA. As defined herein, the phrase "selectively mixed composition" includes a composition produced in a manner such that the ratio of pantothenate to HMBPA is a controlled
15 feature, i.e., the ratio of pantothenate to HMBPA is selected. The selection can occur by manipulating the microorganism producing the composition (i.e., the production strain) such that one component is favored for production over the other.

In one aspect, the invention features a process for the production of a selectively mixed pantothenate:HMBPA composition that includes culturing a
20 microorganism having a deregulated pantothenate biosynthetic pathway under conditions such that a selectively mixed pantothenate:HMBPA composition is produced. In one embodiment, the microorganism is cultured under conditions that favor pantothenate production. In another embodiment, the microorganism is cultured under conditions that favor HMBPA production. In another embodiment, the microorganism
25 is cultured under conditions of controlled steady state glucose that favor pantothenate production. In another embodiment, the microorganism is cultured under conditions of controlled steady state glucose that favor HMBPA production. In yet another embodiment, the microorganism is cultured under conditions of controlled steady state dissolved oxygen that favor pantothenate production. In yet another embodiment, the
30 microorganism is cultured under conditions of controlled steady state dissolved oxygen that favor HMBPA production. In yet another embodiment, the microorganism is cultured under conditions of controlled serine levels that favor pantothenate production. In one embodiment, the composition comprises pantothenate and HMBPA at a ratio of 75 mol pantothenate to 25 mol HMBPA or greater. In another embodiment, the
35 composition comprises pantothenate and HMBPA at a ratio of 90 mol pantothenate to 10 mol HMBPA or greater. In another embodiment, the composition comprises

pantothenate and HMBPA at a ratio of 75 mol HMBPA to 25 mol pantothenate or greater. In yet another embodiment, the composition comprises pantothenate and HMBPA at a ratio of 90 mol HMBPA to 10 mol pantothenate or greater. Values and ranges included and/or intermediate of the values set forth herein are also intended to be

5 within the scope of the present invention.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by

10 reference.

EXAMPLES

Example I: Discovery and Characterization of the [R]-3-(2-hydroxy-3-methyl-butrylamino)-propionic acid (HMBPA) Biosynthetic Pathway

5 In developing *Bacillus* strains for the production of pantothenate, various genetic manipulations are made to genes and enzymes involved in the pantothenate biosynthetic pathway and the isoleucine-valine (*ilv*) pathway (Figure 1) as described in U.S. Patent Application Serial No. 09/400,494 and U.S. Patent Application Serial No. 09/667,569. For example, strains having a deregulated *panBCD* operon and/or having
10 deregulated *panE1* exhibit enhanced pantothenate production (when cultured in the presence of β -alanine and α -ketoisovalerate (α -KIV)). Strains further deregulated for *ilvBNC* and *ilvD* exhibit enhanced pantothenate production in the presence of only β -alanine. Moreover, it is possible to achieve β -alanine independence by further deregulating *panD*.

15 An exemplary strain is PA824, a tryptophan prototroph, Spec and Tet resistant, deregulated for *panBCD* at the *panBCD* locus, deregulated for *panE1* at the *panE1* locus (two genes in the *B. subtilis* genome are homologous to *E. coli panE*, *panE1* and *panE2*, the former encoding the major ketopantoate reductase involved in pantothenate production, while *panE2* does not contribute to pantothenate synthesis
20 (U.S. Patent Application Serial No. 09/400,494), deregulated for *ilvD* at the *ilvD* locus, overexpressing an *ilvBNC* cassette at the *amyE* locus, and overexpressing *panD* at the *bpr* locus.

Under the following fermentation conditions, PA824 routinely yields approximately 20-30 g/L pantothenate. The production of pantothenate by PA824 in
25 this example is accomplished in 14 L fermentor vessels. The composition of the batch and feed media are as follows.

BATCH

	MATERIAL	g/L (final)
1	Yeast extract	10
2	Na Glutamate	5
3	(NH ₄) ₂ SO ₄	8
4	KH ₂ PO ₄	5
5	K ₂ HPO ₄	7.6

Added After Sterilization and Cool Down

1	Glucose	2.5
2	CaCl ₂	0.1
3	MgCl ₂	1
4	Sodium Citrate	1
5	FeSO ₄ ·7 H ₂ O	0.01
5	SM-1000X	1 ml

- The final volume of the batch medium is 6 L. The trace element solution
- 5 SM-1000X has following composition: 0.15 g Na₂MoO₄·2 H₂O, 2.5 g H₃BO₃, 0.7 g CoCl₂·6 H₂O, 0.25 g CuSO₄·5 H₂O, 1.6 g MnCl₂·4 H₂O, 0.3 g ZnSO₄·7 H₂O are dissolved in water (final volume 1L).

- The batch medium was inoculated with 60 ml of shake flask PA824 culture (OD=10 in SVY medium: Difco Veal Infusion broth 25 g, Difco Yeast extract 5
- 10 g, Sodium Glutamate 5 g, (NH₄)₂SO₄ 2.7 g in 740 ml H₂O, autoclave; add 200 ml sterile 1 M K₂HPO₄ (pH 7) and 60 ml sterile 50% Glucose solution (final volume 1L)). The fermentation was run at 43 °C at an air flow rate of 12 L/min as a glucose limited fed batch. The initial batched glucose (2.5 g/L) was consumed during exponential growth. Afterwards glucose concentrations were maintained between 0.2-1 g/L by continuous
- 15 feeding of FEED solution as follows.

FEED

	MATERIAL	g/L (final)
1	Glucose	550
2	CaCl ₂	0.1
3	SM-1000X	3 ml

- The variable feed rate pump was computer controlled and linked to the glucose concentration in the tank by an algorithm. In this example the total feeding was
- 20 6L.

During fermentation the pH was set at 7.2. Control was achieved by pH measurements linked to computer control. The pH value was maintained by feeding either a 25% NH₃-solution or a 20% H₃PO₄-solution. NH₃ acts simultaneously as a N-

source for the fermentation. The dissolved oxygen concentration $[pO_2]$ was set at 30% by regulation of the agitation and aeration rate. Foaming was controlled by addition of silicone oil. After the stop of the addition of the feed solution, in this example after 48 hours, the fermentation was continued until the $[pO_2]$ value reached 95%. Then the fermentation was stopped by killing the microorganism through sterilization for 30 min. The successful sterilization was proven by plating a sample of the fermentation broth on agar plates. The pantothenate titer in the fermentation broth was 21.7 g/L after sterilization and removal of the cells by centrifugation (determined by HPLC analysis).

For HPLC analysis the fermentation broth sample was diluted with sterile water (1:40). 5 μ l of this dilution was injected into a HPLC column (Aqua C18, 5 μ m, 150x2.0 mm, Phenomenex™). Temperature of the column was held at 40°C. Mobile phase A was 14.8 mM H_3PO_3 , mobile phase B 100% Acetonitrile. Flow rate was constant at 0.5 mL/min. A gradient was applied :

	start:	2% mobile phase B
15	0-3 min	linear increase to 3% mobile phase B
	3-3.5 min	linear increase to 20% mobile phase B

The detection was carried out by an UV-detector (210 nm). Run time was 7 min with an additional 3 min posttime. The retention time for pantothenic acid is 3.9 minutes. The HPLC chromatogram for the above mentioned sample is given in Figure 4.

Identification of a compound related to the peak with retention time 4.7 minutes

In addition to producing significant quantities of pantothenate, it was discovered a second compound eluted with an approximate retention time of 4.7 minutes in this system. The second prominent product formed in the fermentation was shown to be 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (HMBPA) (also referred to herein as “ β -alanine 2-(R)-hydroxyisovalerate”, “ β -alanine 2-hydroxyisovalerate”, “ β -alanyl- α -hydroxyisovalerate” and/or “pantothenate”). It was identified by its mass spectrum (Figure 5; relative monoisotopic mass 189), and by 1H - and ^{13}C -NMR after chromatographic purification by reverse phase flash chromatography (mobile phase 10 mM KH_2PO_4 , with increasing contents of acetonitrile (1-50%)) (data not shown). The compound was presumed to have the R configuration at the asymmetric carbon by analogy with [R]-pantothenate.

In order to verify the identity of the compound, deliberate synthesis of racemic β -alanine 2-hydroxyisovalerate was performed as follows. β -alanine (2.73 g / 30 mmol) and sodium methoxide (5.67 g of a 30% solution in methanol / 31.5 mmol) were dissolved in methanol (40 mL). Methyl 2-hydroxyisovalerate (2-hydroxy-3-

methylbutyric acid methyl ester) (3.96g / 30 mmol) was added and refluxed for 18 hours. Methanol was then removed by rotavap and replaced by tert-butanol (50 mL). Potassium tert-butoxide was added (50 mg) and refluxed for 26 hours. The solvent was removed *in vacuo*, the residue dissolved in water (50 mL) and passed through a strongly
5 acidic ion-exchange resin (H⁺-form Lewatite™ S 100 G1; 100 mL). More water is used to rinse the ion exchanger. The aqueous eluates are combined and the water removed *in vacuo*. The residue is subjected to flash chromatography (silica gel; 2% acetic acid in ethyl acetate as eluent) and the product fractions evaporated to give a solid residue. The
10 residue was recrystallized from ethyl acetate / toluene (10 mL / 20 mL, respectively) and analytically pure HMBPA (β -alanine 2-hydroxyisovalerate) was obtained, which showed a relative monoisotopic mass of 190 (189 + H⁺) in the mass spectrometer and the same ¹H-NMR resonances as the product obtained from fermentation.

The biosynthetic pathway resulting in HMBPA production is set forth in Figure 2. The chemical structure of [R]-3-(2-hydroxy-3-methyl-butrylamino)-
15 propionic acid (HMBPA) is depicted in Figure 3. As depicted in Figure 2, HMBPA is the condensation product of [R]- α -hydroxyisovaleric acid (α -HIV) and β -alanine, catalyzed by the PanC enzyme. α -HIV is generated by reduction of α -KIV, a reaction that is catalyzed by the α -keto reductases PanE (*e.g.*, PanE1 and/or PanE2) and/or IlvC.

Based on the chemical structure and biosynthetic pathway leading to
20 HMBPA production, the present inventors have formulated the following model to describe the interaction between the previously known pantothenate and isoleucine-valine (*ilv*) pathways and the newly characterized HMBPA biosynthetic pathway. In at least one aspect, the model states that there exist at least two pathways in microorganisms that compete for α -KIV, the substrate for the biosynthetic enzyme
25 PanB, namely the pantothenate biosynthetic pathway and the HMBPA biosynthetic pathway. (A third and fourth pathway competing for α -KIV are those resulting in the production of valine or leucine from α -KIV, see *e.g.*, Figure 1). At least the pantothenate biosynthetic pathway and the HMBPA biosynthetic pathway further produce competitive substrates for the enzyme PanC, namely α -HIV and pantoate.
30 Production of HMBPA has significant effects on pantothenate production. Most importantly, the HMBPA pathway competes with the pantothenate pathway for precursors (α -KIV and β -alanine) and for some of the enzymes (PanC, PanD, PanE1, and/or IlvC). In addition, because the structure of HMBPA is similar to that of pantothenate, it may have the undesirable property of negatively regulating one or more
35 steps in the pantothenate pathway. The model predicts that production of pantothenate can be improved or optimized by any means which favor use of substrates (α -KIV and

β -alanine) and/or enzymes (PanC, PanD, PanE1, and/or IlvC) in pantothenate biosynthetic processes as compared to HMBPA biosynthetic processes.

A preferred approach to maximize pantoate and/or pantothenate production while minimizing HMBPA production is to increase the activity of PanB in the cells because this will decrease the availability of α -KIV for α -HIV synthesis while promoting the synthesis of ketopantoate and pantoate. Methods of increasing activity include overexpressing the *panB* gene, increasing the copy number of the gene, increasing the specific activity of the enzyme and/or relieving inhibition of the enzyme by mutation or by lowering Coenzyme A levels. Higher pantoate levels in turn increase pantothenate synthesis and decrease HMBPA synthesis by out competing α -HIV for PanC.

Another approach to maximize pantothenate synthesis is to optimize the level of *panE1* expression. It is demonstrated herein that increasing production of PanE1 increases the synthesis of HMBPA at the expense of pantothenate. Accordingly, effecting a moderate decrease in the level of *panE1* expression in PA824 or PA668 (*i.e.*, precisely regulating the level of *panE1* expression) will result in a decrease in HMBPA synthesis and an increase in pantothenate synthesis. Moreover, as shown in Example II, deletion of *panE2* significantly decreases HMBPA synthesis.

Other approaches to increasing pantoate and/or pantothenate synthesis versus HMBPA synthesis include optimizing α -KIV production levels in the cells and/or isolating a modified PanC protein with increased preference for pantoate as a substrate.

The following examples provide experimental support for the model described herein and further exemplify processes for increasing the production of pantoate and/or pantothenate (relative to HMBPA levels) based on the model.

EXAMPLES II-VIII:

For Examples II-VI, quantitation of pantothenate and/or HMBPA was performed as follows. Aliquots of fermentation media were diluted 1:100 and aliquots of test tube cultures were diluted 1:10 in water or 5% acetonitrile prior to injection on a Phenomenex Aqua™ 5 μ C18 HPLC column (250 x 4.60mm, 125A). Mobile phases were A = 5% acetonitrile, 50 mM monosodium phosphate buffer adjusted to pH 2.5 with phosphoric acid; and B = 95% acetonitrile, 5% H₂O.

Linear gradients were as follows.

Minutes	Solvent A	Solvent B
0	100%	0%
16	100%	0%
17	0%	100%
20	0%	100%
21	100%	0%

Additional parameters and apparatus were as follows: Flow rate = 1.0
 5 ml/min; Injection volume = 20 μ l; Detector = Hewlett Packard 1090 series DAD UV
 detector-3014, Signal A = 197 nm, ref. = 450 nm, Firmware revision E; Column heater =
 Oven temperature 40°C; Hardware = Hewlett Packard Kayak™ XA; and Software =
 Hewlett Packard Chemstation Plus™ family revision A.06.03[509].

HMBPA elutes at approximately 13 minutes in this system.

10

Example II: Decreasing HMBPA Synthesis by Deleting PanE2 From Pantothenate Production Strains

As described in Example I, HMBPA production was first observed in
 15 microorganisms overexpressing *panE1* indicating that ketopantoate reductase is capable
 of catalyzing not only the reduction of ketopantoate to pantoate but also the reduction of
 α -ketoisovalerate to 2-hydroxyisovalerate. As mentioned previously, two genes in the
B. subtilis genome are homologous to the *E. coli panE* gene encoding ketopantoate
 reductase and have been named *panE1* and *panE2*. In *Bacillus*, it has been demonstrated
 20 that the *panE1* gene encodes the major ketopantoate reductase involved in pantothenate
 production, whereas *panE2* does not contribute to pantothenate synthesis. Moreover,
 overexpression of *panE2* from a *P*₂₆*panE2* cassette in pAN238 (SEQ ID NO:25) leads
 to a reduction in pantothenate titer (see *e.g.*, U.S. Patent Application Serial No.
 09/400,494). Given the homology between the *panE2* and *panE1* gene products and the
 25 fact that overexpression of *panE2* shifted production away from pantoate/pantothenate, it
 was tested whether *panE2* contributed in any significant manner to the production of
 HMBPA. It was hypothesized that the *panE2* gene product is an enzyme capable of

reducing α -KIV to α -HIV, but incapable of significantly reducing ketopantoate to pantoate.

To test the hypothesis, *panE2* was deleted from pantothenate production strain PA824 (described in Example I) by transforming with a Δ *panE2::cat* cassette
5 from chromosomal DNA of strain PA248 (Δ *panE2::cat*) (set forth as SEQ ID NO:24, for construction see *e.g.*, U.S. Patent Application Serial No. 09/400,494) to give strain PA919. Three isolates of PA919 were compared to PA824 for pantothenate and HMBPA production in test tube cultures grown in SVY plus β -alanine.

Table 1. Production of pantothenate and HMBPA by derivatives of PA824 and PA880 grown at 43°C in 48 hour test tube cultures of SVY glucose + β -alanine⁵.

Strain	new trait	parent	OD ₆₀₀	[pan] g/l	[HMBPA] g/l
PA824	—	parent	13.9	4.3	0.64
PA880	Δ coaX	PA824	16.4	5.1	0.48
PA894	Δ coaX, coaA(S151L), cat	PA880	14.9	4.9	0.47
PA911-5	P ₂₆ panB@ vpr, Δ coaX	PA880	13.4	5.3	0.40
PA911-8	P ₂₆ panB@ panB, Δ coaX	"	13.8	6.1	0.45
PA919-1	Δ panE2::cat	PA824	13.2	4.2	0.15
PA919-2	"	"	14.8	3.8	0.13
PA919-3	"	"	18.0	5.5	0.14

As indicated by the data in Table 1, all three isolates of PA919 produced about four-fold lower HMBPA than PA824 demonstrating that the *panE2* gene product contributed to HMBPA production and demonstrating that HMBPA production can be at least partially eliminated by simply deleting *panE2*, without sacrificing pantothenate production.

Example III. HMBPA Production and Pantothenate Production are Inversely Correlated.

Strains derived from PA365 (the RL-1 lineage equivalent of PA377, described in U.S. patent application Serial No. 09/667,569) which are deleted for the *P₂₆ panBCD* cassette and which contain a *P₂₆ panC*D* cassette amplified at the *vpr* locus and either the wild type *P₂₆ panB* cassette (PA666) or a *P₂₆ ΔpanB* cassette (PA664) amplified at the *bpr* locus were constructed as follows. An alignment of the C-terminal amino acids of known or suspected PanB proteins is shown in Figure 6. Three regions called 1, 2 and 3 were identified having conserved or semi-conserved amino acid residues that are indicated by arrows at the top of the figure. The *B. subtilis* PanB protein (RBS02239) is underlined. Two of the PanB proteins (RCY14036 and CAB56202.1) are missing region 3 while the latter PanB protein is also missing region 2 and has non-conserved amino acid residues occupying region 1.

B. subtilis PanB variants were created that were missing regions 1, 2 and 3. The desired variants were created by designing 3' PCR primers to amplify the *B. subtilis panB* gene such that region 3, regions 2 and 3, or all three regions would be missing from the final product. The PCR products were generated and cloned into *E. coli* expression vector pASK-1BA3, creating plasmids pAN446, pAN447, and pAN448, respectively. The plasmids were then transformed into *E. coli* strain SJ2 that contains the *panB6* mutation to test for complementation. Only pAN446, which is missing region 3, was able to complement. This indicates that region 3 is not essential for *B. subtilis* PanB activity but that region 2 is required for activity or stability.

The next step in this analysis was to transfer the *panB* gene from pAN446 to a *B. subtilis* expression vector and then introduce it into a strain appropriate for testing activity of the encoded PanB protein in *B. subtilis*. To do this, a strain that is deleted for the *P₂₆ panBCD* operon was first created. This was accomplished by first inserting a *cat* gene between the *Bse*RI site located just upstream of the *panB* RBS and the *Bg*/II site located in *panD*, creating plasmid pAN624, SEQ ID NO:20 (Figure 7).

The resulting deletion-substitution mutation ($\Delta panBCD::cat624$), which removes all of *panB* and *panC*, was crossed into PA354 by transformation, with selection for resistance to chloramphenicol on plates supplemented with 1 mM pantothenate. One of the transformants was saved and named PA644. Chromosomal DNA isolated from PA644 was analyzed by PCR and was shown to contain the deletion-substitution mutation. As expected, PA644 requires pantothenate for growth but retains the engineered *ilv* genes ($P_{26}ilvBNC$ $P_{26}ilvD$) as well as the $P_{26}pan$ *E1* gene originally present in PA354. Thus, it has all the enzymes involved in pantoate synthesis overproduced except PanB. The gene containing the shortest *panB* deletion was inserted into *B. subtilis* expression vector pOTP61 (described in US patent application Serial No. 09/667,569), creating plasmid pAN627. At the same time, a wild-type *panB* control gene was inserted into pOTP61, creating plasmid pAN630. The *NotI* fragments of each plasmid, lacking *E. coli* vector sequences, were ligated and transformed into PA644, with selection for resistance to tetracycline.

One transformant from each transformation was saved and further transformed with chromosomal DNA from PA628 with selection for Pan⁺. PA628 contains a multicopy $P_{26}panC^*D$ expression plasmid (*pAN620*) integrated at the *vpr* locus. In order to determine the effects of the *panB* gene mutation directly on pantothenate production, plasmid pAN620 SEQ ID NO:21, which is illustrated in Figure 8, provides the remaining two enzymes required for pantothenate synthesis (PanC and PanD). Four transformants from each transformation were isolated, grown in SVY medium containing 10 g/L aspartate for 48 hours, then assayed for pantothenate production. Transformants with the 3' deleted *panB* gene were named PA664 and those containing the wild-type gene were called PA666. The data showed that the 3' deleted *panB* gene in PA664 encodes a PanB protein with greatly reduced activity. To test for HMBPA production, test tube cultures of PA365, PA666, and PA664 were grown in SVY + aspartate medium with and without added α -KIV or pantoate for 48 hours and then assayed for HMBPA and pantothenate as described previously.

Table 2. Effect of PanB activity and addition of precursors on HMBPA and pantothenate production, 48 hour test tube culture data, SVY + aspartate (10 g/L) medium.

Strain	pan operon	panC*D plasmid	panB plasmid	no additions		+ α -KIV (5 g/L)		+ pantoate (5 g/L)	
				[pan] (g/L)	HMBPA peak*	[pan] (g/L)	HMBPA peak	[pan] (g/L)	HMBPA peak
PA365	<i>P₂₆ panBCD</i>	NONE	NONE	3.0	0.71	3.2	1.28	4.8	0.38
PA666	<i>ΔpanBCD::cat</i>	pAN620	pAN630	3.7	0.55	3.3	1.70	5.2	0.26
PA664	<i>ΔpanBCD::cat</i>	pAN620	pAN627	0.3	1.39	0.6	1.76	2.5	0.74

* HMBPA peak = peak area $\times 10^{-3}$

The data presented in Table 2 demonstrate that in the absence of supplements, PA666 produced the least HMBPA whereas PA664 produced the most, indicating an inverse correlation between PanB activity and HMBPA production. This is consistent with the model which predicts that the two pathways compete for α -KIV, the substrate for PanB, and produce competitive substrates for PanC; lowering PanB activity would be expected to increase α -KIV availability for α -HIV synthesis and correspondingly decrease the amount of pantoate synthesized. When α -KIV is added to the medium, all three strains produced significantly more HMBPA. This result implies that α -KIV is a precursor to HMBPA, as described in Figure 2, and that excess α -KIV favors HMBPA production. This result also suggests that synthesis of HMBPA is at least partially due to an overflow effect of excess α -KIV production. When pantoate was added to the medium, HMBPA was reduced by roughly 50 percent in all three strains. Conversely, the strains each produced significantly more pantothenate. This result is also consistent with the model that the two pathways produce competing substrates for PanC (α -HIV and pantoate). Taken together, the above results further indicate that increasing pantoate synthesis should be beneficial in promoting pantothenate production as well as reducing HMBPA levels. Moreover, factors that decrease pantoate synthesis negatively affect pantothenate synthesis.

Example IV. Effect of Increasing PanB and/or Regulating PanE1 on Production of Pantothenate

PA668 is a derivative of PA824 that contains extra copies of *P₂₆ panB* amplified at the *vpr* or *panB* locus. PA668 was constructed using the *panB* expression vector (pAN636, SEQ ID NO:22) which allows for selection of multiple copies using chloramphenicol (Figure 9). The pAN636 *NotI* restriction fragment, missing the *E. coli* vector sequences, was ligated and then used to transform PA824 with selection on plates containing 5 μ g/ml chloramphenicol. Transformants resistant to 30 μ g/ml chloramphenicol were isolated and screened for pantothenate production in 48 hour test tube cultures. The isolates shown produce less HMBPA than PA824 (conversely producing about 10 percent more pantothenate than PA824). A second strain, called PA669, was constructed which is PA824 with extra copies of *P₂₆ panE1* amplified at the *vpr* or *panE1* locus. Strain PA669 was constructed by transforming PA824 with the self-ligated *NotI* fragment of plasmid pAN637, SEQ ID NO:23 (Figure 10) with selection for resistance to chloramphenicol. Two isolates of PA669 were chosen for

further study; PA669-5 produces less PanE1 than PA669-7 as judged by SDS-PAGE analysis of total cell extracts made from the two strains.

- Test tube cultures of strains PA824, PA668-2, PA668-24, and the two isolates of PA669 (PA669-5 and PA669-7) were grown in three different media (SVY, SVY + aspartate, and SVY + aspartate + pantoate) for 48 hours and then assayed for pantothenate, HMBPA, and β -alanine (Table 3).
- 5

Table 3. Effect of extra copies of *panB* and *panE1* on pantothenate and HMBPA production by PA824, 48 hour test tube culture data, SVY medium.

Strain	<i>panB</i> plasmid	<i>panE</i> plasmid	no additions			+ aspartate (10 g/L)			+ aspartate (10 g/L) & pantoate (5 g/L)		
			[pan] (g/L)	[β-ala] (g/L)	HMBPA *	[pan] (g/L)	[β-ala] (g/L)	HMBPA	[pan] (g/L)	[β-ala] (g/L)	HMBPA
PA824	NONE	NONE	1.8	0.05	<0.1	4.7	2.5	0.53	5.6	2.5	<0.10
PA668-2	pAN636	NONE	1.5	<0.04	<0.1	5.0	1.6	<0.10	4.9	1.2	<0.10
PA668-24	pAN636	NONE	1.8	0.05	<0.1	4.9	2.8	0.34	6.1	2.6	<0.10
PA669-5	NONE	pAN637	1.8	0.04	<0.1	4.2	3.1	0.74	5.8	2.6	0.30
PA669-7	NONE	pAN637	1.8	0.06	<0.1	3.7	3.2	1.41	5.2	2.5	0.75

* HMBPA = peak area X 10⁻³

None of the strains produced detectable quantities of HMBPA in SVY medium. All strains produced roughly equivalent amounts of pantothenate and low amounts of β -alanine indicating that β -alanine is limiting for both pantothenate and HMBPA synthesis in these cultures and that β -alanine is a precursor for both compounds. When grown in SVY + aspartate medium, the two PA669 isolates produced more HMBPA than PA824 whereas both PA668 isolates produced less HMBPA than PA824. It is noteworthy that the strain that produces the most PanE1 (PA669-7) produced the most HMBPA (and the least pantothenate). This suggests that high levels of PanE1 favor the production of HMBPA at the expense of lower pantothenate synthesis. It is also interesting that PA668-24 produced more HMBPA than PA668-2, even though SDS-PAGE analysis of extracts from the two strains showed that they produce roughly equivalent levels of PanB. The SDS-PAGE analysis also showed that PA668-24 makes much more IlvC than PA668-2. Based on these data, it is proposed that IlvC influences HMBPA synthesis by increasing steady state levels of α -KIV and/or by catalyzing α -HIV formation from α -KIV, thereby accounting for the observed shift towards production of HMBPA.

The final set of data in Table 3 shows that adding pantoate to the growth medium decreased HMBPA production by all strains that had previously produced detectable levels, *e.g.*, by shifting synthesis towards pantothenate. This further supports the model that α -HIV and pantoate are competitive substrates for PanC.

Example V: Increasing Pantothenate Synthesis by Reduction of Pantothenate Kinase in Production Strains

One strategy to increase pantothenate production is to reduce the amount of pantothenate kinase activity in production strains. Pantothenate kinase is the first enzyme in the pathway from pantothenate to Coenzyme A. It was hypothesized that lower pantothenate kinase activity would lead to lower steady state levels of Coenzyme A, which could in turn lead to higher PanB enzyme activity and higher titers of pantothenate. As described in U.S. patent application 09/667,569, two unlinked genes have been identified in *B. subtilis* that both encode pantothenate kinase, 1) *coaA*, which is homologous to the essential *E. coli* pantothenate kinase gene, and 2) *coaX*, which represents a novel class of bacterial pantothenate kinase genes.

Either *coaA* or *coaX* can be deleted from a wild type *B. subtilis* strain without any apparent effect on growth on rich or minimal medium. However, it is not possible to generate strains having a deletion in both genes, suggesting that one or the other is necessary for viability. Therefore, a strain was constructed having a deleted
5 *coaX* and then *coaA* was mutated to reduce the specific activity of the CoaA enzyme. Although the phenotypes of the Δ *coaX*, mutated *coaA* strains are subtle, the data is consistent with the hypothesis that PanB activity can be increased by restricting pantothenate kinase activity. This in turn decreases HMBPA production and increases pantothenate production.

10

Installation of Δ coaX and mutated coaA alleles into PA824.

Deletion of *coaX* from PA824 was accomplished in a single step by transforming PA824 to kanamycin resistance with chromosomal DNA from PA876 (PY79 Δ *coaX::kan*), described in U.S. patent application 09/667,569, to give PA880.
15 The *coaX* deletion in PA880 and PA876 was derived ultimately from plasmid pAN336 (SEQ ID NO:26, see U.S. Patent Application Serial No. 09/667,569). Next, a control version of a wild type *coaA* gene and two mutated alleles of *coaA* were introduced as follows. The control and two mutated alleles were first introduced into the chromosome of wild type strain PY79 using transformation to chloramphenicol resistance by
20 plasmids, and then chromosomal DNA from these intermediate strains was used to transform PA880 to chloramphenicol resistance. The plasmids used to integrate the control and mutant alleles were pAN294 (SEQ ID NO:27, see U.S. Patent Application Serial No. 09/667,569), pAN343, and pAN344. pAN343 is almost identical to pAN294, except that it contains a T to C base change at base number 3228 of pAN294. Similarly,
25 pAN344 has a CC to TA change at base numbers 3217 and 3218 of pAN294. All three plasmids have a chloramphenicol resistance gene (*cat*) substituting for the dispensable gene of unknown function, *yqjT*, that lies just downstream from *coaA*. The intermediate strains derived from PY79 by double crossovers of pAN294 (wild type *coaA*, *yqjT::cat*), pAN343 (*coaA2 Y155H*, *yqjT::cat*), and pAN344 (*coaA2 S151L*, *yqjT::cat*), are named
30 PA886, PA887, and PA888, respectively. Next, PA880 was transformed to chloramphenicol resistance with chromosomal DNA from PA886, PA887, or PA888, to give strains PA892 (wild type *coaA*, *cat*), PA893 (*coaA Y155H*, *cat*), and PA894 (*coaA S151L*, *cat*), respectively. Eight candidates for PA893 were checked for acquisition of the Y155H mutation by PCR of the *coaA* gene and *Nla*III digestion, and all eight were
35 correct.

Several candidates for each new strain, including PA880, were assayed for pantothenate production at 43° in standard test tube cultures grown in SVY medium plus 5 g/l β -alanine (see Table 4).

Table 4. Production of pantothenate and pantothenate by derivatives of PA824 that have been deleted for *coaX* and mutated for *coaA*, grown at 43°C in 48 hour test tube cultures of SVY glucose + β -alanine.

Strain	<i>coaA</i>	<i>coaX</i>	OD ₆₀₀	[pan] g/l	[HMBPA] g/l
PA824	wt	wt	11.1	4.4	0.77
PA824	wt	wt	11.4	4.1	0.70
PA880	wt	Δ	11.6	5.5	0.33
PA880	wt	Δ	12.7	5.1	0.33
PA892-1	wt, <i>cat</i>	Δ	11.7	4.5	0.26
PA892-2	wt, <i>cat</i>	Δ	13.4	4.5	0.26
PA892-3	wt, <i>cat</i>	Δ	12.9	4.8	0.25
PA893-1	Y155H, <i>cat</i>	Δ	10.7	4.3	0.24
PA893-2	Y155H, <i>cat</i>	Δ	12.0	4.5	0.25
PA893-3	Y155H, <i>cat</i>	Δ	11.9	4.7	0.23
PA893-4	Y155H, <i>cat</i>	Δ	12.8	4.3	0.20
PA893-5	Y155H, <i>cat</i>	Δ	11.6	4.7	0.28
PA893-8	Y155H, <i>cat</i>	Δ	10.0	4.7	0.25
PA894-1	S151L ?, <i>cat</i>	Δ	11.6	4.6	0.29
PA894-2	S151L ?, <i>cat</i>	Δ	15.6	4.5	0.27
PA894-3	S151L ?, <i>cat</i>	Δ	12.3	5.0	0.31
PA894-4	S151L ?, <i>cat</i>	Δ	12.2	5.0	0.27
PA894-5	S151L ?, <i>cat</i>	Δ	11.8	4.5	0.26
PA894-6	S151L ?, <i>cat</i>	Δ	11.2	4.7	0.27
PA894-7	S151L ?, <i>cat</i>	Δ	13.1	4.7	0.26
PA894-8	S151L ?, <i>cat</i>	Δ	13.2	4.8	0.32

In medium containing β -alanine, PA894 (S151L), but not PA893 (Y155H) gave, on average, slightly higher pantothenate levels than PA892 (the isogenic strain with wild type *coaA*). PA880 gave significantly higher pantothenate (5.5 and 5.1 g/l) than its isogenic parent, PA824 (4.4 and 4.1 g/l), and slightly higher pantothenate levels than PA894 (average about 4.7 g/l). It is possible that the *AyqjT::cat* insertion present in PA892, PA893, and PA894 (but not PA880) has an effect that counteracts any gain that might result from the mutated *coaA* alleles.

Despite the narrow range of pantothenate titers from the new strains, a highly significant pattern was observed for production of HMBPA. In all strains where *coaX* was deleted, the HMBPA titer was two- to three-fold lower than for PA824. This is consistent with the principle that HMBPA production results in part from a limitation in PanB activity. Consequently, Δ *coaX* leads to increased *PanB* activity.

Example VI: Increasing Pantothenate Synthesis by Combined Increase in PanB and Reduction of Pantothenate Kinase in Production Strains

PA668, which contains an extra PanB expression cassette that is designed to be amplified by chloramphenicol (see Example IV), produces more pantothenate and less HMBPA than its predecessor, PA824. Since deletion of *coaX* from PA824 also reduces HMBPA production and moderately improves pantothenate production (PA880), a strain combining the two modifications was constructed and tested for pantothenate production. Plasmid pAN636 (Figure 9) was digested with *NotI*, ligated into circles, and used to transform PA880 to chloramphenicol resistance to give strain PA911. Several isolates of PA911 were tested by PCR to determine whether the plasmid had integrated at *vpr* as intended, or at *panB*, where it can also integrate. Both types were found. One isolate of each type of PA911, PA911-5 and PA911-8, were amplified on tetracycline (*panD* cassette) and chloramphenicol (*panB* cassette) and tested for pantothenate production in test tube cultures grown in SVY plus β -alanine (see Table 1). Both isolates produced more pantothenate, and slightly less HMBPA than their parent, PA880. Moreover, consistent with the PA668 isolates, PA911-8, which has the *panB* cassette integrated at *panB*, produced the highest level of pantothenate.

Example VII: Increasing Pantothenate Production by Increasing Serine Availability

It was hypothesized that the ratio of pantothenate to HMBPA production could also be controlled by regulating the availability of serine in the microorganism cultures. In particular, it was proposed that increasing the availability of serine could increase pantothenate production relative to HMBPA production, whereas decreasing the availability of serine would decrease the production of pantothenate relative to HMBPA production. This method is based on the understanding that the PanB substrate, methylenetetrahydrofolate, is derived from serine. Thus, regulating serine levels should effectively regulate PanB substrate levels. To test this hypothesis, PA824 was grown in test tube cultures of SVY glucose plus 5 g/L β -alanine and \pm 5 g/L serine for 48 hours and 43°C.

Table 5: *Production of pantothenate and HMBPA by PA824 with and without the addition of serine*

serine added at 5 g/L	OD ₆₀₀	[pan] g/L	[HMBPA] g/L
-	16.3	4.9	0.84
-	14.0	4.5	0.80
+	13.1	6.4	0.56
+	12.9	6.0	0.62

As demonstrated by the data presented in Table 5, addition of serine increases the level of production of pantothenate while conversely decreasing HMBPA production. As an alternative to feeding serine, another method of increasing serine and methylenetetrahydrofolate levels in order to regulate pantothenate production levels is to increase synthesis or the activity of 3-phosphoglycerate dehydrogenase or of serine hydroxymethyl transferase (the *serA* and *glyA* gene products, respectively), thereby increasing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms.

Example VIII: Pantothenate Production with strains PA668-2A and PA668-24 in 10-Liter Fermentors with Soy Flour Based Medium

Stains PA668-2A and PA668-24 were each grown twice in 10 liter fermentors. The medium was PFM-155 and the composition is as follows.

5

BATCH

	MATERIAL	g/L (final)
1	Amberex 1003	5
2	Cargill 200/20 (soy flour)	40
3	Na Glutamate	5
4	(NH ₄) ₂ SO ₄	8
5	MgSO ₄ ·7H ₂ O	1
6	MAZU DF204C	1
7	H ₂ O	qs to 4 L

Added After Sterilization and Cool Down

1	KH ₂ PO ₄	10
2	K ₂ HPO ₄ ·3H ₂ O	20
3	H ₂ O	qs to 400 ml
1	80% Glucose	20
2	CaCl ₂ ·2H ₂ O	0.1
1	Sodium Citrate	1
2	FeSO ₄ ·7H ₂ O	0.01
3	SM-1000X	1 X

FEED

	MATERIAL	g/L (final)
1	80% Glucose	800
2	CaCl ₂ ·2H ₂ O	0.8
3	H ₂ O	qs to 3500 ml

Added After Sterilization and Cool Down

10

1	Sodium Citrate	2.0
2	FeSO ₄ ·7H ₂ O	0.02
3	SM-1000X	2 X
4	Glutamate Na	5.0
5	H ₂ O	qs to 500 ml

The pantothenate production by PA668-2A was 45 g/L and 51 g/L at 36 hours, similar to routine PA824 fermentations in the same medium. After 36 hours, when pantothenate production routinely begins to slow with PA824, both PA668-2A fermentations continued production to yield 63 g/l pantothenate at 48 hours. Most significantly, the production of HMPBA at 48 hours was reduced to 3-5 g/L, and was less than 5% of the pantothenate during most of the earlier fermentation. Clear benefits to pantothenate synthesis are evident from the increased levels of PanB in strain PA668. Strain PA668-24 produced pantothenate at an even faster rate with the two fermentations averaging 58 g/L after 36 hours.

10

Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

15

What is claimed:

1. A process for the production of a HMBPA-free pantothenate composition, comprising
5 culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions such that a HMBPA-free pantothenate composition is produced.
2. The process of claim 1, wherein said microorganism has at least
10 two pantothenate biosynthetic enzymes deregulated.
3. The process of claim 1, wherein said microorganism has at least three pantothenate biosynthetic enzymes deregulated.
- 15 4. The process of claim 1, wherein said microorganism has at least four pantothenate biosynthetic enzymes deregulated.
5. The process of claim 4, wherein said microorganism has a deregulated ketopantoate hydroxymethyltransferase, a deregulated ketopantoate
20 reductase, a deregulated pantothenate synthetase and a deregulated aspartate- α -decarboxylase.
6. The process of any one of claims 1 to 5, wherein said microorganism further has a deregulated isoleucine-valine (*ilv*) biosynthetic pathway.
25
7. The process of claim 6, wherein said microorganism has at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.
8. The process of claim 6, wherein said microorganism has at least
30 three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.
9. The process of claim 8, wherein said microorganism has a deregulated acetohydroxyacid acid synthetase, a deregulated acetohydroxyacid isomeroreductase, and a deregulated dihydroxyacid dehydratase.
35

10. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, said microorganism having PanB activity regulated such that a HMBPA-free
5 pantothenate composition is produced.

11. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway,
10 said microorganism having PanE1 activity regulated such that a HMBPA-free pantothenate composition is produced.

12. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway,
15 said microorganism having PanE2 activity regulated such that a HMBPA-free pantothenate composition is produced.

13. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway,
20 said microorganism having IlvC activity regulated such that a HMBPA-free pantothenate composition is produced.

14. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway,
25 said microorganism having PanB and PanE1 activities regulated such that a HMBPA-free pantothenate composition is produced.

15. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway,
30 said microorganism having PanB and PanE2 activities regulated such that a HMBPA-free pantothenate composition is produced.

16. A process for the production of a HMBPA-free pantothenate composition comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, said microorganism having PanB and IlvC activities regulated such that a HMBPA-free
5 pantothenate composition is produced.

17. The process of any one of claims 10, 14, 15 and 16, wherein PanB activity is increased by overexpressing PanB.

10 18. The process of any one of claims 10, 14, 15 and 16, wherein PanB activity is increased by expressing multiple copies of the *panB* gene.

19. The process of any one of claims 10, 14, 15 and 16, wherein Pan B activity is increased by decreasing feedback inhibition of PanB.

15 20. The process of claim any one of claims 10, 14, 15 and 16, wherein PanB activity is increased by regulating pantothenate kinase activity.

20 21. The process of claim 20, wherein pantothenate kinase activity is decreased.

22. The process of claim 21, wherein CoaA is deleted and CoaX is downregulated.

25 23. The process of claim 21, wherein CoaX is deleted and CoaA is downregulated.

24. The process of claim 21, wherein CoaX and CoaA are downregulated.

30 25. The process of claim 10, 14 or 15, wherein PanE activity is decreased by deleting the *panE2* gene.

26. The process of claim 10, 14 or 15, wherein PanE activity is
35 decreased by regulating expression of the *panE* gene.

27. The process of claim 13 or 15, wherein *IlvC* activity is decreased by regulating expression of the *ilvC* gene.
28. The process of any one of the above claims, wherein said
5 microorganism is cultured under conditions of reduced steady state glucose.
29. The process of any one of the above claims, wherein said microorganism is cultured under conditions of increased steady state dissolved oxygen.
30. The process of any one of the above claims, wherein said
10 microorganism is cultured under conditions of excess serine.
31. The process of any one of the above claims, wherein said microorganism has the pantothenate biosynthetic pathway deregulated such that
15 pantothenate production is independent of β -alanine feed.
32. The process of claim any one of the above claims, wherein said microorganism overexpresses the *panD* gene such that pantothenate production is independent of β -alanine feed.
20
33. The process of any one of the above claims wherein the microorganism belongs to the genus *Bacillus*.
34. The process of any one of the above claims, wherein the
25 microorganism is *Bacillus subtilis*.
35. A product synthesized according to the process of any one of the above claims.
36. A HMBPA-free pantothenate composition synthesized according
30 to the process of any one of the above claims.
37. A composition synthesized by a microorganism having a deregulated pantothenate biosynthetic pathway, wherein said composition comprises
35 pantothenate and is essentially free of HMBPA.

38. A recombinant microorganism for the production of HMBPA-free compositions of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) pathway, and having PanB or PanE1 selectively regulated.

5

39. A recombinant microorganism for the production of HMBPA-free compositions of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) pathway, and having PanB and PanE1 selectively regulated.

10

40. A recombinant microorganism for the production of HMBPA-free compositions of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) pathway, and having PanB or PanE2 selectively regulated.

15

41. A recombinant microorganism for the production of HMBPA-free compositions of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) pathway, and having PanB and PanE2 selectively regulated.

20

42. A recombinant microorganism for the production of HMBPA-free compositions of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) pathway, and having PanE1 deleted, PanE2 deleted and IlvC overexpressed.

25

43. The microorganism of any one of claims 38-42 belonging to the genus *Bacillus*.

44. The microorganism of any one of claims 38-42 which is *Bacillus subtilis*.

30

45. A process for the production of a selectively mixed pantothenate:HMBPA composition, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions such that a selectively mixed pantothenate:HMBPA composition is produced.

35

46. The process of claim 45, wherein the microorganism is cultured under conditions that favor pantothenate production.

5 47. The process of claim 45, wherein the microorganism is cultured under conditions that favor HMBPA production.

48. The process of claim 45 or 46, wherein the microorganism is cultured under conditions of controlled steady state glucose that favor pantothenate
10 production.

49. The process of claim 45 or 47, wherein the microorganism is cultured under conditions of controlled steady state glucose that favor HMBPA
15 production.

50. The process of claim 45 or 46, wherein the microorganism is cultured under conditions of controlled steady state dissolved oxygen that favor pantothenate production.

20 51. The process of claim 45 or 47, wherein the microorganism is cultured under conditions of controlled steady state dissolved oxygen that favor HMBPA production.

52. The process of claim 45 or 46, wherein the microorganism is
25 cultured under conditions of controlled serine levels that favor pantothenate production.

53. The process of claim 45 or 46, wherein the microorganism has modifications that favor pantothenate production.

30 54. The process of claim 45 or 47, wherein the microorganism has modifications that favor HMBPA production.

55. A product produced by the process of any one of claims 45-54.






FIG 1

Figure 2. Proposed pathway for biosynthesis of HMBPA.





[R]-3-(2-hydroxy-3-methyl-butrylamino)-propionic acid ("HMBPA")


FIG 3

```

=====
Injection Date   :                               Seq. Line :   42
Sample Name     :   8                           Vial       :   41
Acq. Operator   :                               Inj         :    1
                                           Inj Volume  : 5 ul

Sequence File   : C:\HPCHEM\2\SEQUENCE\VIT-B2.S
Method          : C:\HPCHEM\2\METHODS\PANTOTHE.M
Last changed    :
Aqua 150*2,0mm
=====

```



```

=====
External Standard Report
=====

```

```

Sorted By       : Signal
Calib. Data Modified :
Multiplier     : 1.0000
Dilution       : 1.0000

```

Signal 1: DAD1 A, Sig=197,6 Ref=off

RetTime (min)	Type	Area (mAU*s)	Amt/Area	Amount (mg/L)	Grp	Name
3.893	VV	4173.96582	9.76719e-2	407.67936		Pantothensäure

Totals : 407.67936

Results obtained with enhanced integrator!

```

=====
*** End of Report ***
=====


```

HPLC - analysis of Fermentation broth

Figure 4

Scans: 1 > 904
Client: Dr. C. Beck
#Peaks: 9349
RIC: 1575177
5.58+05

SPEC: Panthotensare.nebenprodukt Probe 4
Samp: LCHS Aqua v. Hr. Seb. H2O/ACN 100:1 NH4OAc pH 4.5 197 nm
Comm: Study:
Oper: Masses: 115.00 > 949.99
Base: 172.10
Peak: 1000.0 m/z
Scan 168 @ 5.59 min (ESI +QIMS APICID LMR UP PROF) (SM 5)



2

ESI 1

Figure 6. An alignment of the C-terminal amino acids from all known or suspected *PanB* proteins.

	1	2	3
	↓	↓	↓
CAA10222.1	AYVAEVKGVTFPCA	EHCFSA	
APE0676	RYAEDVRNGRFFCE	EHVH	AKEPLEDIS
RYP04152	LYTEVVDGGLYFAE	EHIFQ	
REC04341	QYMAEVESGVYFGE	EHSEH	
sp Q09672	RYTYEVEQGLYFAE	EHSEQ	
RNG01188	AYVAEVKAKTFFAA	EHIFAD	
RNM00107	AYVAEVKAKTFFAA	EHIFAD	
RPA02174	AYVRAVKDVSFFAA	EHGFNA	
RCA00999	SYAKEVREGTFEDE	AHSFK	IDQSIIDETK
REF01843	KYIEEVKDGVEFGP	EHGFK	ISDVLEKLY
RQJ02253	KYRDEVKSGIFFSQ	EHSE	DYLDDELLDKLY
RBS02239	GYVQDVRHRAFFEQ	KHSFQ	MNQTVLDGLYGCK
RDR03436	HYAAEVRAREFFSK	DSEFV	MKDEVLDKLY
RCY14036	KFSGEVRCROFFERR	G	
RPA08114	RFAEDVRERRFFEA	RHCFAMRE	
RRC02991	AYAAEVRSAFFAP	EHSE	DEVKK
SCC75A.02	AYAEDEVGGTFFAD	EHSVH	
CAA65397.1	AYTADTHAGTFFCE	AESF	
CAB56202.1	EWAAAEKLN		
RMT01063	QYAQEVAGGVFFAD	EHSE	
sp Q10505	QYAQEVAGGVFFAD	EHSE	
RML00370	QYAEVASAVFFAE	EHCF	
RML00622	QYAEVASAVFFAE	EHCF	
RAA01082	NFKIDVEGGNFFSE	EESYG	
RHP00462	QYADDVKKGNFFNE	LESYH	
RPG00121	HYTADVKSDFENK	EHY	
RPH00184	TFREEVKKEGFFGR	EHWEFQDKEEFKRIK	DNVMKKLNL
RPF00767	EFRKEVKEGFFGK	EHWWEYQDKETFNRIKEN	VMRKLRL
TMI728	EFREVKKEGFFTE	EHSE	TDKSKGVSS
PAB0570	EFKQDVKEGFFGR	EHWWEFQDKEEFKRIKES	VLAKVD
PSC03568	EYIASVEDRTFFERG	THIFKVKEDLWNEFLSS	INEK
AAD37248.1	QYREEVKSRAVFAE	QHLYPIPKELVEFQKAVDEL	PZEK
T3F17.24	SYKEEVSKVFFGP	SHSPYKITASELDGFLTELQKLGFDKAASAAALAAENMERSK	

Figure 7. Construction of pAN624.




Figure 8. Construction of pAN620.




Figure 9 . Construction of pAN636.





Figure 10 . Construction of pAN637.

SEQUENCE LISTING

<110> Omnigene Bioproducts

<120> PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

<130> BGI-148PC

<140>

<141>

<160> 27

<170> PatentIn Ver. 2.0

<210> 1

<211> 194

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter
sequence

<220>

<221> -35_signal

<222> (136)..(141)

<220>

<221> -10_signal

<222> (159)..(164)

<400> 1

gctattgacg acagctatgg ttactgtcc accaaccaaa actgtgctca gtaccgcca 60
tatttctccc ttgaggggta caaagagggtg tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgggg 180
gcaaccccg cgtg 194

<210> 2

<211> 163

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter
sequence

<220>

<221> -35_signal

<222> (113)..(118)

<220>

<221> -10_signal

<222> (136)..(141)

<400> 2
gcctacctag cttccaagaa agatataccta acagcacaag agcggaaaga tgttttgttc 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120
atctacaagg tgtggtataa taatcttaac aacagcagga cgc 163

<210> 3
<211> 127
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:promoter
sequence

<220>
<221> -35_signal
<222> (34)..(39)

<220>
<221> -10_signal
<222> (58)..(63)

<220>
<221> -35_signal
<222> (75)..(80)

<220>
<221> -10_signal
<222> (98)..(103)

<400> 3
gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatTTaaatt ttatttgaca aaaatgggct cgtgttgtac aataaatgta gtgaggtgga 120
tgcaatg 127

<210> 4
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 4
taaacatgag gaggagaaaa catg 24

<210> 5
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 5
attcgagaaa tggagagaat ataatatg 28

<210> 6
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 6
agaaaggagg tga 13

<210> 7
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<223> All occurrences of n = any nucleotide

<400> 7
ttaagaaagg aggtgannnn atg 23

<210> 8
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<223> All occurrences of n = any nucleotide

<400> 8
ttagaaagga ggtgannnnn atg 23

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<223> All occurrences of n = any nucleotide

<400> 9
agaaaggagg tgannnnnnn atg 23

<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<223> All occurrences of n = any nucleotide

<400> 10
agaaaggagg tgannnnnna tg 22

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 11
ccctctagaa ggaggagaaa acatg 25

<210> 12
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 12
ccctctagag gaggagaaaa catg 24

<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 13
ttagaaagga ggatttaa atg 23

<210> 14
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome binding site

<400> 14

ttagaaagga ggtttaatta atg

23

<210> 15

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome binding site

<400> 15

ttagaaagga ggtgatttaa atg

23

<210> 16

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome binding site

<400> 16

ttagaaagga ggtgttttaa atg

23

<210> 17

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome binding site

<400> 17

attcgagaaa ggaggtgaat ataatatg

28

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome binding site

<400> 18

attcgagaaa ggaggtgaat aataatg

27

<210> 19

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ribosome binding site

<400> 19

attcgtagaa aggaggtgaa ttaatatg

28

<210> 20

<211> 6886

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN624

<400> 20

```

aagaaaccaa ttgtccatat tgcacagac attgccgtca ctgcgtcttt tactggctct 60
tctcgctaac caaaccggtta accccgctta ttaaaagcat tctgtaacaa agcgggacca 120
aagccatgac aaaaacgcgt acaaaaagt tctataatca cggcagaaaa gtccacattg 180
attatttgca cggcgtcaca ctttgctatg ccatagcatt tttatccata agattagcgg 240
atcctacctg acgcttttta tcgcaactct ctactgtttc tccatacccg ttttttggg 300
ctaacaggag gaattaacca tggatccgag ctgcagagta tcaagcactt cacaatctgg 360
gagctgaaag cccgccttat gtagctcata cttgacaaat ccaaggtcaa aatggatatt 420
gtgggcgaca aaataagcgc cgtcaagcaa ttggaatact tcttcagcaa ctgcttcaaa 480
tggctgttca ttctcgacca ttgattaga gattccagta agctgctcaa taaaagcagg 540
gattgattta tttggattaa tgtattttga aaaccgctca gtaatttgtc cattttcgat 600
tacaaccgct gcgatttgta tgattttatc gcctttcttc ggcgaattcc ctggtgtctc 660
tacatctata acaacgaacc gttgcttatt cattaaaatg gacacctcaa ttcttgata 720
cgacaaaagt gtaacacgtt ttgtacggaa atggagcggc aaaaccgttt tactctcaa 780
atcttaaaag aaaacccccg ataaaggggg cttttcttct acaaaattgt acgggctgg 840
tcgttcccca gcatttgttc aattttgttt tgatcattca gaacagccac tttcggtca 900
tggcttgccg cttcttgatc agacatcatt ttgtaggaaa taataatgac cttatctcct 960
tctgcacaa ggcggtgcgc tgcaccgttt aagcatatga cgccgcttcc cgtttacca 1020
ggaataatat acgtttcaag acgtgctcca ttattattat tcacaatttg tactttttca 1080
ttaggaatat ttcccacagc atcaatgaga tctctagag tcgacctgca ggcagcaag 1140
cttcgctcga cgctctccct tatgcgactc ctgcattagg aagcagccca gtatgaggt 1200
gaggccgttg agcaccgccg ccgcaaggaa tgggtgcatgc aaggagatgg cgcccaacag 1260
tccccgggcc acggggcctg ccaccatacc cagccgaaa caagcgctca tgagcccgaa 1320
gtggcgagcc cgatcttccc catcggtgat gtcggcgata taggcgccag caaccgcacc 1380
tgtggcgccg gtgatgccgg ccacgatgag tccggcgtag aggatcaatc ttcatccatt 1440
ccaaggtaaa tcccccttcg ccgtttctgt taccattata caccttttga accttaacgt 1500
aaacgttaag ttttaaaaaa caataaaaaa gacgagcagc atacagcacc cgtctttcac 1560
tttctgtttt aagctaaact tcccgccact gacagagact ctttttgaag gctttcagaa 1620
agcactcgat acgcatctg gagctgtaat ataaaaacct tcttcaacta acggggcagg 1680
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 1740
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 1800
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 1860
tattaatgaa ttttctgctg gtaataatgg gtagaaggta attactatta ttattgatat 1920
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 1980
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaaggt 2040
ataaatcata aaactctttg aagtacttct ttacaggagt ccaaatacca gagaatggtt 2100
tagatacacc atcaaaaatt gtataaagt gctctaactt atcccaataa cctaactctc 2160
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 2220
aaataaatgc agggtaaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 2280

```


tatcaatttc	tgtggttata	ctaaaagtcg	tttgttggtt	caaataatga	ttaaataatct	2340
cttttctctt	ccaattgtct	aatcaattt	tattaaagtt	catttgatat	gcctcctaaa	2400
tttttatcta	aagtgaattt	aggaggtcta	cttgtctgct	ttcttcatta	gaatcaatcc	2460
ttttttaaaa	gtcaatatata	ctgtaacata	aatatatatt	ttaaaaaatat	cccactttat	2520
ccaattttcg	tttgttgaac	taatgggtgc	tttagttgaa	gaataaagac	cacattaaaa	2580
aatgtggtct	tttgtgtttt	tttaaaggat	ttgagcgtag	cgaaaaatcc	ttttctttct	2640
tatcttgata	ataagggtaa	ctattgcatg	ataagctgtc	aaacatgaga	attcccgttt	2700
tctctgcaa	gccaaaaaac	cttcogttac	aacgagaagg	attcttcact	ttctaaagtt	2760
cggcgagttt	catccctctg	tcccagtcct	tttttggaac	aaggcagact	gctgcaatgt	2820
ctatctattt	taataatagg	tgcagttcgc	aggcgatact	gcccaatgga	agtataccaa	2880
aatcaacggg	cttgtagcaa	cacattagcc	caattcgata	tcggcagaat	agattttttt	2940
aatgccttcg	ttcgttttcta	aaagcagaac	gccttcacata	tctataccta	acgccttacc	3000
gtaaaagggt	ccgttttaacg	ttctggctct	catattagtg	ccaataccga	gcgcatagct	3060
ttcccataaa	agcttaaatcg	gcgtaaatcc	gtgcgtcata	taatcccgtt	accgtttctc	3120
aaagcatagt	aaaatatgct	ggatgacgcc	ggcccgatca	attttttccc	cagcagcttg	3180
gctgaggctt	gtcgcgatgt	ccttcaattc	atctggaaaa	tcattaggtc	gctggttaaa	3240
cggctctccag	cttggctggt	ttggcggatg	agagaagatt	ttcagcctga	tacagattaa	3300
atcagaacgc	agaagcggtc	tgataaaaaca	gaatttgctt	ggcggcagta	gcgcgggtgt	3360
cccacctgac	cccattgccga	actcagaagt	gaaacgcctg	agcgcggatg	gtagtgtggg	3420
gtctcccat	gcgagatgag	ggaactgcca	ggcatcaaat	aaaacgaaag	gctcagtcga	3480
aagactgggc	ctttcggtttt	atctgtgtgt	gtcgggtgaa	cgctctcctg	agtaggacaa	3540
atccgcgggg	agcggatttg	aacgttgcca	agcaacggcc	cggagggtgg	cgggcaggac	3600
gcccgccata	aactgccagg	catcaaatta	agcagaaggc	catcctgacg	gatggccttt	3660
ttcggtttct	acaaactcct	tttgtttatt	tttctaaata	cattcaaata	tgtatccgct	3720
catgagacaa	taaccctgat	aaatgcttca	ataatattga	aaaaggaaga	gtatgagtat	3780
tcaacatttc	cgtgtcgccc	ttattccctt	ttttgcggca	ttttgccttc	ctgtttttgc	3840
tcaccagaa	acgtgtgtga	aagtaaaaga	tgctgaagat	cagttgggtg	cacgagtggg	3900
ttacatcgaa	ctggatctca	acagcggtaa	gatccttgag	agttttcgcc	ccgaagaacg	3960
ttttccaatg	atgagcactt	ttaaagtctt	gctatgtggc	gcggtattat	cccgtgttga	4020
cgccgggcaa	gagcaactcg	gtcgcgcgat	acactattct	cagaatgact	tggttgagta	4080
ctaccagtc	acagaaaagc	atcttacgga	tgcatgaca	gtaagagaat	tatgcagtgc	4140
tgccataacc	atgagtgata	acactgcggc	caacttactt	ctgacaacga	tcggaggacc	4200
gaaggagcta	accgcttttt	tgcaacaat	gggggatcat	gtaactcgcc	ttgatcgttg	4260
ggaaccggag	ctgaatgaag	ccataccaaa	cgacgagcgt	gacaccacga	tgctgtgagc	4320
aatgggcaaca	cgtgtgcgca	aactattaac	tgcggaacta	cttactctag	cttcccgaca	4380
acaattaata	gactggatgg	aggcggataa	agttgcagga	ccacttctgc	gctcggccct	4440
tcgggtgtgc	tggtttattg	ctgataaatc	tgagccgggt	gagcgtgggt	ctcgcggtat	4500
cattgcagca	ctggggccag	atggtaaagg	ctcccgatc	gtagtattct	acacgacggg	4560
gagtcaggca	actatggatg	aacgaaatag	acagatcgct	gagataggtg	cctcactgat	4620
taagcatttg	taactgtcag	accaagttta	ctcatatata	cttttagattg	atttaaaact	4680
tcatttttaa	tttaaaagga	tctaggtgaa	gatccttttt	gataatctca	tgacccaaaat	4740
cccttaacgt	gagttttcgt	tccactgagc	gtcagacccc	gtagaaaaga	tcaaaggatc	4800
ttcttgagat	cccttttttct	tgcgcgtaat	ctgctgcttg	caaacaaaaa	aaccaccgct	4860
accagcgggt	gtttgtttgc	cggatcaaga	gctaccaact	ctttttccga	aggtaactgg	4920
cttcagcaga	gcgcagatac	caaatactgt	ccttctagt	tagccgtagt	tagggccacca	4980
cttcaagaac	tctgtagcac	cgctacata	cctcgctctg	ctaactcctg	taccagtggc	5040
tgtgccagt	ggcgataagt	cgtgtcttac	cgggttgga	tcaagacgat	agttaccgga	5100
taaggcgcag	cggtcgggct	gaacgggggg	ttcgtgcaca	cagcccagct	tgagcgaac	5160
gacctacacc	gaactgagat	acctacagcg	tgagctatga	gaaagcgcca	cgcttcccga	5220
aggagagaaag	gcggacagg	atccggtaag	cggcagggtc	ggaacaggag	agcgacagag	5280
ggagcttcca	gggggaaacg	cctggtatct	ttatagtcct	gtcgggtttc	gccacctctg	5340
acttgagcgt	cgatttttgt	gatgctcgtc	aggggggcgg	agcctatgga	aaaacggcag	5400
caacgcggcc	tttttacggt	tcctggcctt	ttgctggcct	tttgctcaca	tgttctttcc	5460
tgcgttatcc	cctgattctg	tggataaccg	tattaccgcc	tttgagttag	ctgataccgc	5520
tcgcccagc	cgaacgacgc	agcgcagcga	gtcagtgagc	gaggaagcgg	aagagcgcct	5580
gatgcggtat	tttctcctta	cgcactctgt	cgttatattca	caccgcata	ggtgcactct	5640
cagtacaatc	tgctctgatg	ccgcatagtt	aagccagtat	acactccgct	atcgctacgt	5700
gactgggtca	tggtgtgcgc	cgcacacccg	ccaacacccg	ctgacgcgcc	ctgacgggct	5760
tgtctgtctc	cggcatccgc	ttacagacaa	gctgtgaccg	tctccgggag	ctgcatgtgt	5820
cagaggtttt	caccgtcatc	accgaaacgc	gcgaggcagc	agatcaattc	gcgcgcgaag	5880

```

gcgaagcggc atgcataatg tgccctgtcaa atggacgaag cagggattct gcaaacccta 5940
tgctactccg tcaagccgtc aattgtctga ttcgttacca attatgacaa cttgacggct 6000
acatcattca ctttttcttc acaaccggca cggaactcgc tcgggctggc cccggtgcat 6060
tttttaata cccgcgagaa atagagttga tcgtcaaaac caacattgcg accgacgggtg 6120
gcgataggca tccgggtggt gctcaaaagc agcttcgcct ggctgatacg ttggtcctcg 6180
cgccagctta agacgctaata ccctaactgc tggcggaata gatgtgacag acgcgacggc 6240
gacaagcaaa catgctgtgc gacgctggcg atatcaaaat tgctgtctgc caggtgatcg 6300
ctgatgtact gacaagcctc gogtaccgga ttatccatcg gtggatggag cgactcgta 6360
atcgcttcca tgcgcgcgag taacaattgc tcaagcagat ttatcgccag cagctccgaa 6420
tagcgccctt ccccttgccc ggcgtaaatg atttgcccaa acaggtcgct gaaatgcggc 6480
tgggtcgctt catccgggcg aaagaacccc gtattggcaa atattgacgg ccagttaagc 6540
cattcatgcc agtaggcgcg cggacgaaag taaaccact ggtgatacca ttcgcgagcc 6600
tccgtagtac gaccgtagtg atgaatctct cctggcgga acagcaaaat atcacccggt 6660
cggcaacaa attctcgtcc ctgatttttc accaccctt gaccgcgaat ggtgagattg 6720
agaatataac ctttcattcc cagcggctcg tcgataaaaa aatcgagata accgttggcc 6780
tcaatcgcg ttaaaccgcg caccagatgg gcattaaacg agtatcccg cagcagggga 6840
tcattttgcg cttcagccat acttttcata ctcccgccat tcagag 6886

```

<210> 21

<211> 7140

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN620

<400> 21

```

tcggcggcgg cttcgtcgac cgaaacagca gttataaggc atgaagctgt ccggtttttg 60
caaaagtggc tgtgactgta aaaagaaatc gaaaaagacc gttttgtgtg aaaacggtct 120
ttttgtttcc ttttaaccaa ctgccataac tcgaggccta cctagcttcc aagaaagata 180
tcctaacagc acaagagcgg aaagatgttt tgttctacat ccagaacaac ctctgctaaa 240
attcctgaaa aattttgcaa aaagtgtgtg actttatcta caaggtgtgg tataataatc 300
ttaacaacag caggacgctc tagattagaa aggaggattt aaatatgaga cagattactg 360
atatttcaca gctgaaagaa gccataaaac aataccattc agagggcaag tcaatcggt 420
ttgttccgac gatgggggtt ctgcatgagg ggcatttaac cttagcagac aaagcaagac 480
aagaaaacga cgccgttatt atgagtattt ttgtgaatcc tgcacaattc ggccctaattg 540
aagattttga agcatatccg cgcgatattg agcgggatgc agctcttgca gaaaacgccc 600
gagtcgatat tctttttacg ccagatgctc atgatatgta tcccggtgaa aagaatgtca 660
cgattcatgt agaaagacgc acagacgtgt tatcgggcg ctcaagagaa ggacattttg 720
acggggtcgc gatcgtagt acgaagcttt tcaatctagt caagccgact cgtgcctatt 780
tcggtttaaa agatgcgcag caggtagctg ttgttgatgg gttaatcagc gacttcttca 840
tggaatttga attgggtcct gtcgatacgg tcagagagga agacggctta gccaaaagct 900
ctcgcaatgt atacttaaca gctgaggaag gaaaagaagc gcctaagctg tatcggggcc 960
ttcaacaag tgcggaactt gtccaagccg gtgaaagaga tcctgaagcg gtgataaaag 1020
ctgcaaaaaga tatcattgaa acgactagcg gaaccataga ctatgtagag ctttattcct 1080
atccggaact cgagcctgtg aatgaaattg ctggaagatg gattctcgct gttgcagttg 1140
ctttttcaaa agcgcgttta atagataata tcattattga tttcgtaga aaggaggtga 1200
attaatatgt atcgtacgat gatgagcggc aaacttcaca gggcaactgt tacggaagca 1260
aacctgaact atgtgggaag cattacaatt gatgaagatc tcattgatgc tgtgggaatg 1320
cttcctaattg aaaaagtaca aattgtgaat aataataatg gagcacgtct tgaaacgtat 1380
attattcctg gtaaacgggg aagcggcgtc atatgcttaa acggtgcagc cgcacgcctt 1440
gtgcaggaag gagataaggt cattattatt tcctacaaaa tgatgtctga tcaagaagcg 1500
gcaagccatg agccgaaagt ggctgttctg aatgatcaaa acaaaattga acaaatgctg 1560
gggaacgaac atacccgtac aattttgtaa aggtcctgt tttggcgat gagagaagat 1620
tttcagcctg atacagatta aatcagaacg cagaagcggg ctgataaaac agaatttgcc 1680
tggcggcagt agcgcggtgg tcccacctga ccccatgccg aactcagaag tgaaacgccc 1740
tagcggccgat ggtagtgtgg ggtctcccca tgcgagagta gggaaactgcc aggcattcaa 1800

```

taaaacgaaa	ggctcagtcg	aaagactggg	cctttcgttt	tatctgttgt	ttgtcgggtg	1860
acgctctcct	gagtaggaca	aatccgcg	gagcggattt	gaacgttgcg	aagcaacggc	1920
ccggagggtg	gcgggcagga	cgcccgccat	aaactgcccag	gcatcaaatt	aagcagaagg	1980
ccatcctgac	ggatggcctt	tttgcgtttc	tacaaactct	tggtagccgag	acgatcgtcc	2040
tctttgttgt	agcccatcac	ttttgctgaa	gagtaggagc	cgaaagtgc	ggcgtattca	2100
ttgagcggca	gctgagtcgc	accgacagaa	atcgcttctc	ttgatgtgcc	cgcgatccg	2160
actgtccagc	cgttcgggcc	gctgttgccg	tttgaggtaa	cagcgacaac	gccttctgac	2220
atggccaggt	caagcgctgt	gcttgtcgcc	cagtcgggt	tgtttaaaga	gtttccgaga	2280
gacaggttca	tcacatctgc	ccgctcctgc	actgcacgtt	ccacgcccgc	gatgacgttt	2340
tccgttgtgc	cgcttccg	agggccctaac	acacgataag	caagaagtgt	ggcatcaggc	2400
gctacgcctt	taatcgcttc	gtttgcagcc	acagttccgg	ctacgtgtgt	gccatgggtca	2460
gttgccctgc	ccctcgatc	gccggttggt	gtttcctttg	gatcgtaatc	attgtccaca	2520
aaatcgatc	ctttatattg	tccaaagttt	ttcttcagat	ctgggtgatt	gtattcaacc	2580
ccagtgtcaa	taatcgccac	cttgatgcct	tttctgtgt	agcctaaatc	ccatgcatcg	2640
tttgctccga	tataaggcgc	actgtcatcc	atttgcggag	atacggcgct	ttcggagatt	2700
gtggggaatt	ctcatgtttg	acagcttatc	atgcaatagt	tacccttatt	atcaagataa	2760
gaaagaaaag	gatttttcgc	tacgctcaaa	tcctttaaaa	aaacacaaaa	gaccacattt	2820
tttaattgtg	tctttattct	tcaactaaag	caccctattg	ttcaacaaac	gaaaattgga	2880
taaagtggga	tatttttaaa	atatatatatt	atgtttacagt	aatattgact	tttaaaaaag	2940
gattgtattct	aatgaagaaa	gcagacaagt	aagcctccta	aattcacttt	agataaaaaat	3000
ttaggaggca	tatcaaatga	actttaataa	aattgattta	gacaattgga	agagaaaaaga	3060
gatatttaat	cattatttga	accaacaaac	gacttttagt	ataaccacag	aaattgatat	3120
tagtgtttta	taccgaaaca	taaaacaaga	aggatataaa	ttttaccctg	cattttatttt	3180
cttagtgaca	aggtgataaa	actcaaatac	agcttttaga	actggttaca	atagcgacgg	3240
agagttaggt	tattgggata	agtttagagcc	actttatata	atttttgatg	gtgtatctaa	3300
aacattctct	ggtatttggg	ctcctgtaaa	gaatgacttc	aaagagtttt	atgattttata	3360
cctttctgat	gtagagaaat	ataatggttc	ggggaaattg	tttcccaaaa	cacctatacc	3420
tgaaaatgct	ttttctcttt	ctattattcc	atggacttca	tttactgggt	tttaacttaaa	3480
tatcaataat	aatagtaatt	accttctacc	cattattaca	gcaggaaaat	tcattaataa	3540
aggtaattca	atatattttac	cgctatcttt	acaggtacat	cattctgttt	gtgatgggtta	3600
tcatgcagga	ttgtttatga	actctattca	ggaattgtca	gataggccta	atgactggct	3660
tttataatat	gagataatgc	cgactgtact	ttttacagtc	ggttttctaa	tgctactaac	3720
ctgccccgtt	agttgaagaa	cgaagcgccc	gcaattcttg	aagacgaaag	ggcctcgtga	3780
tacgcctatt	tttatagggt	taataatggt	ttcttagacg	tcagggtggca	tcagggtggca	3840
cctttcgggg	aaatgtgcgc	ggaaccctca	tttgtttatt	tttctaaata	cattcaaaata	3900
tgtatccgct	catgagacaa	taaccctgat	aaatgcttca	ataatattga	aaaaggaaga	3960
gtatgagtat	tcaacatttc	cgtgtcgccc	ttattccctt	ttttgcggca	ttttgccttc	4020
ctgtttttgc	tcacccagaa	acgctggtga	aagtaaaaga	tgctgaagat	cagttgggtg	4080
cacgagtggg	ttacatcgaa	ctggatctca	acagcggtaa	gatccttgag	agttttcgcc	4140
ccgaagaacg	ttttccaatg	atgagcactt	ttaaagttct	gctatgtggc	gcgggtattat	4200
cccgtattga	cgccgggcaa	gagcaactcg	gtcgccgcat	acactattct	cagaatgact	4260
tggttgagta	ctccacagtc	acagaaaagc	actttacgga	tggcatgaca	gtaagagaat	4320
tatgcagtgc	tgccataaoc	atgagtgata	acactgcggc	caacttactt	ctgacaacga	4380
tcggaggacc	gaaggagcta	accgcttttt	tgcaacaacat	gggggatcat	gtaactcgcc	4440
ttgatcggtg	ggaaccggag	ctgaatgaag	ccataccaaa	cgacgagcgt	gacaccacga	4500
tgcttcgagc	aatggcaaca	acgttgcgca	aactattaac	tggcgaaacta	cttactctag	4560
cttcccggca	acaattaata	gactggatgg	aggcggataa	agttgcagga	ccacttctgc	4620
gctcggccct	tccggctggc	tggtttattg	ctgataaatc	tgagccgggt	gagcgtgggt	4680
ctcgcggtat	cattgcagca	ctggggccag	atggtaaagc	ctcccgatc	gtagttatct	4740
acacgacggg	gagtcaggca	actatggatg	aacgaaatag	acagatcgct	gagataggtg	4800
cctcactgat	taagcattgg	taactgtcag	accaagttta	ctcatatata	cttttagattg	4860
atttaaaact	tcatttttaa	tttaaaagga	tctaggtgaa	gatccttttt	gataatctca	4920
tgacaaaaat	cccttaacgt	gagttttcgt	tccactgagc	gtcagacccc	gtagaaaaga	4980
tcaaaggatc	ttcttgagat	cctttttttc	tgcgcgtaat	ctgctgcttg	caaacaaaaa	5040
aaccaccgct	accagcggtg	gtttgtttgc	cggatcaaga	gctaccaact	ctttttccga	5100
aggtaactgg	cttcagcaga	gcgcagatac	caaatactgt	ccttctagtg	tagccgtagt	5160
taggccacca	cttcaagaac	tctgtagcac	cgctacata	cctcgctctg	ctaactctgt	5220
taccgtggc	tgctgccagt	cgcgataagt	cgtgtcttac	cgggttgagc	tcaagacgat	5280
agttaccgga	taaggcgagc	cggtcgggct	cagcgggggg	ttcgtgcaca	cagcccagct	5340
tggagcgaac	gacctacacc	gaactgagat	acctacagcg	tgagctatga	gaaagcgcca	5400

```

cgcttcccga agggagaaaag gcggacaggt atccggtaag cggcagggtc ggaacaggag 5460
agcgcacgag ggagcttcca gggggaaaacg cctgggtatct ttatagtcct gtcgggtttc 5520
gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg agcctatgga 5580
aaaacgccaag caacgcggcc tttttacggt tccctggcct ttgctggcct tttgctcaca 5640
tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc tttgagttag 5700
ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagttagc gaggaagcgg 5760
aagagcgctt gatgcggtat tttctcctta cgcctctgtg cgggtatttca caccgcatac 5820
ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagtat aactcgcgtc 5880
atcgctacgt gactgggtca tggctgcgcc ccgacaccgg ccaacaccgg ctgacgcgcc 5940
ctgacgggct tgtctgctcc cggcatccgc ttacagacaa gctgtgaccg tctccgggag 6000
ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgaggcagc tgcggtaaa 6060
ctcatcagcg tggctgtgaa gcgattcaca gatgtctgcc tgttcacccg cgtccagctc 6120
gttgagtttc tccagaagcg ttaatgtctg gcttctgata aagcgggcca tgttaagggc 6180
ggttttttcc tgtttgggtc cttgatgcct ccgtgtaagg gggaatttct gttcatgggg 6240
gtaatgatac cgatgaaacg agagaggatg ctcacgatac gggttactga tgatgaacat 6300
gcccggttac tggaacgttg tgagggtaaa caactggcgg tatggatgag gcggggaccg 6360
agaaaaatca ctcagggtca atgccagcgc ttcggttaata cagatgtagg tgttccacag 6420
ggtagccagc agcatcctgc gatgcagatc cggaaacataa tgggtgcaggg cgtgacttc 6480
cgcgtttcca gactttacga aacacggaaa ccgaagacca ttcattgttg tgcctcaggtc 6540
gcacacgttt tcgacgagca gtcgcttcac gttcgctcgc gtatcggtga ttcattctgc 6600
taaccagtaa ggcaaccccg ccagcctagc cgggtcctca acgacaggag cagcatcatg 6660
cgcaccctg gccaggaccc aacgctgccg gagatgcgcc gcgtgcggct gctggagatg 6720
gcggacgcga tggatatgtt ctgccaaggg ttggtttgcg cattcacagt tctccgcaag 6780
aattgattgg ctccaattct tggagtgttg aatccgttag cgaggtgccg ccggcttcca 6840
ttcagggtca ggtggcccg ctccatgcac cgcgacgcaa cgcggggagg cagacaagg 6900
atagggcggc gctacaatc catgccaaac cgttccatgt gctcgccgag gcggcataaa 6960
tcgcccgtgac gatcagcggt ccagtgatcg aagttaggct ggtaagagcc gcgagcgatc 7020
cttgaagctg tccctgatgg tcgtcatcta cctgcctgga cagcatggcc tgcaacgcgg 7080
gcatcccgat gccgccggaa gcgagaagaa tcataatggg gaaggccatc cagcctcgcg 7140

```

<210> 22

<211> 6725

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN636

<400> 22

```

tcggcgcccg cttcgtcgac cgaacacgca gttataaggc atgaagctgt ccgggtttttg 60
caaaagtggc tgtgactgta aaaagaaatc gaaaaagacc gttttgtgtg aaaacggctc 120
ttttgtttcc ttttaaccaa ctgccataac tcgaggccta cctagcttcc aagaaagata 180
tcctaacagc acaagagcgg aaagatgttt tgttctacat ccagaacaac ctctgctaaa 240
attcctgaaa aattttgcaa aaagtgtgtg actttatcta caaggtgtgg tataataatc 300
ttaacaacag caggacgctc tagaaggagg agaaaacatg aaaacaaaac tggattttct 360
aaaaatgaag gactctgaag aaccgattgt catgctgacc gcttatgatt atccggcagc 420
taaaacttgct gaacaagcgg gagttgacat gattttagtc ggtgattcac ttggaatggt 480
cgtcctcggc cttgattcaa ctgtcgggtg gacagttgcg gacatgatcc atcatacaaa 540
agccgttaaa aggggtgcgc cgaatacctt tattgtgaca gatatgccgt ttatgtctta 600
tcacctgtct aaggaagata cgctgaaaaa tgcagcggtc atcgttcagg aaagcggagc 660
tgacgcactg aagcctgagg gcggaagaag cgtgtttgaa tccattcgcg cattgacgct 720
tggaggcatt ccagtagtca gtcacttagg tttgacaccg cagtcaagtc gcgtactggg 780
cggctataaa gtacagggca aagacgaaca aagcgccaaa aaattaatag aagacagtat 840
aaaaatgcga gaagcaggag ctatgatgct tgtgtggaa tgtgtgccgg cagaactcac 900
agccaaaatt gccgagacgc taagcatacc ggtcattgga atcggggctg gtgtgaaagc 960
ggacggacaa gttctcgttt atcatgatat tatcgccac ggtgttgaga gaacacctaa 1020
atltgtaaag caatatacgc gcattgatga aaccatcgaa acagcaatca gcggatatgt 1080

```

tcaggatgta	agacatcgtg	ctttccctga	acaaaagcat	tcctttcaaa	tgaaccagac	1140
agtgccttgac	ggcttgtagc	ggggaaaata	agggggggat	cctgtttttg	cggatgagag	1200
aagattttca	gcctgatata	gattaaatca	gaacgcagaa	gcggtctgat	aaaacagaat	1260
ttgcttgccg	cgagttagcg	gggtgtccca	cctgacccca	tgccgaactc	agaagtgaat	1320
cgccgtagcg	ccgatggtag	tgtggggtct	ccccatgcga	gagtagggaa	ctgccaggca	1380
tcaaataaaa	cgaaaggctc	agtcgaaaga	ctgggccttt	cgttttatct	gttgtttgtc	1440
ggatgaacgct	ctcctgagta	ggacaaatcc	gccgggagcg	gatttgaacg	ttgcgaagca	1500
acggcccgga	gggtggcggg	caggacgccc	gccataaact	gccaggcatc	aaattaagca	1560
gaaggccatc	ctgacggatg	gcctttttgc	gtttctacaa	actcttggtg	ccgagacgat	1620
cgtcctcttt	gttgtagccc	atcacttttg	ctgaagagta	ggagccgaaa	gtgacggcgt	1680
attcattgag	cggcagctga	gtcgcaccga	cagaaatcgc	ttctcttgat	gtgcccgccg	1740
atccgactgt	ccagccgttc	ggtcgcgtgt	tgcggtttga	ggtaacagcg	acaacgcctt	1800
ctgacatggc	ccagtcaagc	gctgtgcttg	tcgcccagtc	cgggttggtt	aaagagtttc	1860
cgagagacag	gttcatcaca	tctgccccgt	cctgcactgc	acgttccacg	cccgcgatga	1920
cgttttccgt	tgtgccgctt	ccgccaggcc	ctaacacacg	ataagcaaga	agtgtggcat	1980
caggcgctac	gcctttaatc	gttccgtttg	cagccacagt	tcgggctacg	tgtgtgccat	2040
ggatcagttgc	ctcgccccctc	ggatcgccgg	ttgggtgttc	ttttggatcg	taatcattgt	2100
ccacaaaatc	gtatccttta	tattgtccaa	agtttttctt	cagatctggg	tgattgtatt	2160
caaccccgag	gtcaataatc	gccaccttga	tgccttttcc	tgtgtagcct	aaatcccatg	2220
catcgtttgc	tccgatataa	ggcgcaactg	ctaccatttg	cggagatacg	gcgtcttcgg	2280
agattgtggg	gaattctcat	gtttgacagc	ttatcatgca	atagttaccc	ttattatcaa	2340
gataagaaag	aaaaggattt	ttcgctacgc	tcaaatcctt	taaaaaaca	caaagacca	2400
cattttttta	tgtggtcttt	attcttcaac	taaagcacc	attagttcaa	caaacgaaaa	2460
ttggataaag	tgggatattt	ttaaaatata	tatttatgtt	acagtaatat	tgacttttaa	2520
aaaaggattg	attctaataa	agaaagcaga	caagtaagcc	tcctaaattc	acttttagata	2580
aaaatttagg	aggcatatca	aatgaacttt	aataaaattg	atttagacaa	ttggaagaga	2640
aaagagatat	ttaatcatta	tttgaaccaa	caaacgactt	ttagtataac	cacagaaatt	2700
gatatttagt	ttttataccg	aaacataaaa	caagaaggat	ataaatttta	ccctgcattt	2760
attttcttag	tgacaagggt	gataaaactc	aatacagctt	ttagaactgg	ttacaatagc	2820
gacggagagt	taggttattg	ggataagtta	gagccacttt	atacaatttt	tgatgggtga	2880
tctaaaacat	tctctggtat	ttggactcct	gtaaagaatg	acttcaaaga	gttttatgat	2940
ttataccttt	ctgatgtaga	gaaatataat	ggttcgggga	aattgtttcc	caaaacacct	3000
atacctgaaa	atgctttttc	tctttctatt	attccatgga	cttcatttac	tgggttttaac	3060
ttaaatataa	ataataatag	taattacctt	ctaccatta	ttacagcagg	aaaatttcatt	3120
aataaaggta	attcaatata	tttaccgcta	tctttacagg	tacatcattc	tgtttgtgat	3180
ggttatcatg	caggattggt	tatgaactct	attcaggaat	tgtagatag	gcctaataac	3240
tggcttttat	aatatgagat	aatgccgact	gtacttttta	cagtcgggtt	tctaatagtca	3300
ctaactgcc	ccgttagttg	agaacgaag	cggccgcaat	tcttgaagac	gaaagggcct	3360
cgtgatacgc	ctatttttat	aggttaatgt	catgataata	atggtttctt	agacgtcagg	3420
tggcactttt	cggggaaaatg	tgcgcggaac	ccctatttgt	ttatttttct	aaatacattc	3480
aaatatgtat	ccgctcatga	gacaataacc	ctgataaatg	cttcaataat	attgaaaaag	3540
gaagagatat	agttatcaac	atttccgtgt	cgcccttatt	cccttttttg	cggcattttg	3600
ccttccctgt	tttgctcacc	cagaaacgct	ggtagaaagta	aaagatgctg	aagatcagtt	3660
gggtgcacga	gtgggttaca	tcgaactgga	tctcaacagc	ggtaagatcc	ttgagagttt	3720
tcgccccgaa	gaacgttttc	caatgatgag	cactttttaa	gttctgctat	gtggcgcggt	3780
attatcccgt	attgacgcgc	ggcaagagca	actcggctcg	cgcatacact	attctcagaa	3840
tgacttggtt	gagtactcac	cagtacacga	aaagcatctt	acggatggca	tgacagtaag	3900
agaattatgc	agtgtgccca	taaccatgag	tgataaact	gcggccaact	tacttctgac	3960
aacgatcgga	ggaccgaagg	agctaaccgc	ttttttgcac	aacatggggg	atcatgtaac	4020
tcgccttgat	cgttggaac	cggagctgaa	tgaagccata	ccaaacgacg	agcgtgacac	4080
cacgatgcct	gcagcaatgg	caacaacggt	gcgcaaaact	ttactggcgc	aactacttac	4140
tctagcttcc	cggcaacaat	taatagactg	gatggaggcg	gataaaagtg	caggaccact	4200
tctgcgctcg	gcccttccgg	ctggctggtt	tattgtctgat	aaatctggag	ccggtgagcg	4260
tgggtctcgc	ggatcatttg	cagcactggg	gccagatggg	aagccctccc	gtatcgtagt	4320
tatctacacg	acggggagtc	aggcaactat	ggatgaacga	aatagacaga	tcgctgagat	4380
aggtgcctca	ctgattaagc	attggtaact	gtcagaccaa	gtttactcat	atatacttta	4440
gattgattta	aaacttcatt	tttaatttaa	aaggatctag	gtgaagatcc	tttttgataa	4500
tctcatgacc	aaaatccctt	aacgtgagtt	ttcgttccac	tgagcgtcag	accccgtaga	4560
aaagatcaaa	ggatcttctt	gagatccttt	ttttctgcgc	gtaatctgct	gcttgcaaac	4620
aaaaaaacca	ccgctaccag	cgggtggtttg	tttgccggat	caagagctac	caactctttt	4680

```

tccgaaggtg actggcttca gcagagcgca gataccaaat actgtccttc tagtgtagcc 4740
gtagttaggc caccacttca agaactctgt agcaccgcct acatacctcg ctctgctaata 4800
cctgtttacca gtggctgtcg ccagtggcga taagtgcgtg cttaccgggt tggactcaag 4860
acgatagtta ccgataaagg cgcagcggtc gggctgaacg gggggttcgt gcacacagcc 4920
cagcttgga gaaacgacct acaccgaact gagataccta cagcgtgagc tatgagaaa 4980
cgccacgctt cccgaaggga gaaaggcgga caggatatccg gtaagcggca gggtcggaac 5040
aggagagcgc acgaggggag ttccaggggg aaacgcctgg tatctttata gtcctgtcgg 5100
gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct 5160
atggaaaaac gccagcaacg cggccttttt acggttcctg gccttttgct ggccttttgc 5220
tcacatgttc tttcctgcgt tatcccctga ttctgtggat aaccgtatta ccgcctttga 5280
gtgagctgat accgctcgcc gcagccgaac gaccgagcgc agcgagtcag tgagcgagga 5340
agcggaaagg cgctgatgc ggtattttct ccttacgcat ctgtgcggtg tttcacaccg 5400
catatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc agtatacact 5460
ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac acccgctgac 5520
gcgcccgtac gggcttctct gctcccggca tccgcttaca gacaagctgt gaccgtctcc 5580
gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag gcagctgcgg 5640
taaagctcat cagcgtggtc gtgaagcgat tcacagatgt ctgcctgttc atccgcgtcc 5700
agctcgttga gtttctccag aagcgttaat gtctggcttc tgataaagcg ggccatgtta 5760
agggcggttt tttcctgttt ggtcacttga tgccctcgtg taagggggaa tttctgttca 5820
tgggggtaat gataccgatg aaacgagaga ggatgctcac gatacgggtt actgatgatg 5880
aacatgcccg gttactggaa cgttgtgagg gtaaacaaact ggcggtatgg atgcggcggg 5940
accagagaaa aatcactcag ggtcaatgcc agcgttcctg taatacagat gtaggtgttc 6000
cacagggtag ccagcagcat cctgcgatgc agatccgga cataatggtg cagggcgctg 6060
acttcccgct ttccagactt tacgaaacac ggaaaccgaa gaccattcat gttgttgctc 6120
aggtcgcaga cgttttgcag cagcagtcgc ttacagttcg ctgcgctatc ggtgattcat 6180
tctgctaacc agtaaggcaa ccccgccagc ctagccgggt cctcaacgac aggagcacga 6240
tcatgcgcac ccgtggccag gacccaacgc tgcccagat gcgccgctg cggtcgtgg 6300
agatggcgga cgcgatggat atgttctgcc aagggttggt ttgcgcattc acagttctcc 6360
gcaagaattg attggctcca attcttgagg tggatgaatcc gttagcgagg tgccgcccgc 6420
ttccattcag gtcgaggtgg cccggctcca tgcaccgca cgcaacgcgg ggaggcagac 6480
aaggtatagg gcggcgcta caatccatgc caaccgctc catgtgctcg ccgaggcggc 6540
ataaatcgcc gtgacgatca gcggtccagt gatcgaagtt aggtggttaa gagccgcgag 6600
cgatccttga agctgtccct gatggtcgtc atctacctgc ctggacagca tggcctgcaa 6660
cgcgggcacc ccgatgccgc cggaagcgag aagaatcata atggggaagg ccattccagcc 6720
tcgcg

```

<210> 23

<211> 6806

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN637

<400> 23

```

tcggcgccg cttcgtcgac cgaaacagca gttataaggc atgaagctgt ccggtttttg 60
caaaagtggc tgtgactgta aaaagaaatc gaaaaagacc gttttgtgtg aaaacggtct 120
ttttgtttcc ttttaaccaa ctgccataac tcgaggccta cctagcttcc aagaaagata 180
tcctaacagc acaagagcgg aaagatgttt tgtttctacat ccagaacaac ctctgctaaa 240
attcctgaaa aattttgcaa aaagtgtttg actttatcta caaggtgttg tataataatc 300
ttaacaacag caggacgctc tagacaattg agatcttaag aaaggagggtg ttaattaatg 360
aagattggaa tcattggcgg aggtcccggt ggtcttttat gcgcctatta tttgtcactt 420
tatcacgacg tgactgttgt gacgagcgcg caagaacagg ctgcggccat tcagtctgaa 480
ggaaatccggc tttataaagg cggggaggaa ttcagggtcg attgcagtgc ggacacgagt 540
atcaattcgg actttgacct gcttgtcgtg acagtgaagc agcatcagct tcaatctgtt 600
ttttcgtcgc ttgaacgaat cgggaagacg aatatattat ttttgcaaaa cggcatgggg 660
catatccacg acctaaaaga ctggcacggt ggccattcca tttatgttgg aatcgttgag 720

```

cacggagctg	taagaaaatc	ggatacagct	gttgatcata	caggcctagg	tgcgataaaa	780
tgagagcgcg	tgcacgatgc	tgaaccagac	cggctgaaca	tcttgtttca	gcataacccat	840
tcggtttttc	cgattttatta	tgagacggat	tggtaccgtc	tgctgacggg	caagctgatt	900
gtaaatgcgt	gtatttaacc	tttaactgcg	ttattgcaag	tgaaaaatgg	agaactgctg	960
acaacgccag	cttatctggc	ttttatgaag	ctgggtatttc	aggaggcatg	ccgcatttta	1020
aaacttgaaa	atgaagaaaa	ggcttgggag	cgggttcagg	ccgtttgtgg	gcaaacgaaa	1080
gagaatcggt	catcaatgct	ggttgacgtc	attggaggcc	ggcagacgga	agctgacgcc	1140
attatcggt	acttattgaa	ggaagcaagt	cttcaaggct	ttgatgccgt	ccacctagag	1200
tttttatatg	gcagcatcaa	agcattggag	cgaaatacca	acaaagtggg	ttactaagga	1260
tcctgttttg	gcggatgaga	gaagattttc	agcctgatac	agattaaatc	agaacgcaga	1320
agcggctctg	taaaacagaa	tttgccctggc	ggcagtagcg	cggtgggtccc	acctgacccc	1380
atgcccgaact	cagaagtga	acgccgtagc	gccgatggta	gtgtgggggtc	tccccatgcy	1440
agagtaggga	actgccaggc	atcaaataaa	acgaaaggct	cagtcgaaag	actgggcctt	1500
tcgttttatc	tgttgtttgt	cgggtgaacgc	tctcctgagt	aggacaaatc	cgccggggagc	1560
ggatttgaa	gttgcggaagc	aacggcccg	aggggtggcg	gcaggacgcc	gcgcataaac	1620
tgccaggcat	caaattaagc	agaaggccat	cctgacggat	ggcctttttg	cgttttctaca	1680
aactcttgg	accgagacga	tcgtcctctt	tgttgtagcc	catcactttt	gctgaagagt	1740
aggagccgaa	agtgcacggc	tattcattga	gcggcagctg	agtcgcaccg	acagaaatcg	1800
cttctcttga	tgtgcccggc	gatccgactg	tccagccgtt	cggtccgctg	ttgccgtttg	1860
aggttaacgc	gacaacgcct	tctgacatgg	ccagtcagct	cgctgtgctt	gtcgcccgct	1920
ccgggttgg	ttaaagagttt	ccgagagaca	ggttcatcac	atctgccccg	tcctgcatgc	1980
cacgttccac	gcccgcgatg	acgttttccg	ttgtgccgct	tccgccaggc	cctaacacac	2040
gataagcaag	aagtgtggca	tcaggcgcta	cgctttta	cgttccgttt	gcagccacag	2100
ttccggctac	gtgtgtgcc	tggtcagttg	cctcgcccct	cggatcgccg	gttgggtgtt	2160
cttttggatc	gtaatcattg	tcacaaaaat	cgtatccttt	atattgtcca	aagtttttct	2220
tcagatctgg	gtgattgtat	tcaaccccag	tgtcaataat	cgccaccttg	atgccttttc	2280
ctgtgtagcc	taaatcccat	gcategtttg	ctccgatata	aggcgactg	tcattccattt	2340
gcggagatac	ggcgctcttcg	gagattgtgg	ggaattctca	tgtttgacag	cttatcatgc	2400
aatagttaac	cttattatca	agataagaaa	gaaaaggatt	tttcgctacg	ctcaaatcct	2460
ttaaaaaac	acaaaagacc	acatttttta	atgtggtctt	tattcttcaa	ctaaagcacc	2520
cattagtcca	acaaacgaaa	attggataaa	gtgggatatt	tttaaaatat	atattttatgt	2580
tacagtaata	ttgactttta	aaaaaggatt	gattctaatt	aagaaagcag	acaagtaagc	2640
ctcctaaatt	cacttttagat	aaaaatttag	gaggcataatc	aaatgaactt	taataaaatt	2700
gatttagaca	attggaagag	aaaagagata	tttaatcatt	atttgaacca	acaaacgact	2760
tttagtataa	ccacagaaat	tgatattagt	gttttatacc	gaaacataaa	acaagaagga	2820
tataaatttt	accctgcatt	tattttctta	gtgacaaggg	tgataaaactc	aaatacagct	2880
tttagaactg	gttacaatag	cgacggagag	ttaggttatt	gggataagtt	agagccactt	2940
tatacaattt	ttgatggtgt	atctaaaaca	ttctctggta	tttggactcc	tgtaaagaat	3000
gacttcaaag	agttttatga	tttatacctt	tctgatgtag	agaaatataa	tggttcgggg	3060
aaattgtttc	ccaaaacacc	tatacctgaa	aatgcttttt	ctctttctat	tattccatgg	3120
acttcatatta	ctgggttta	cttaaatatc	aataataata	gtaattacct	tctacccatt	3180
attacagcag	gaaaattcat	taataaaggt	aattcaatat	atttaccgct	atctttacag	3240
gtacatcatt	ctgtttgtga	tggttatcat	gcaggattgt	ttatgaactc	tattcaggaa	3300
ttgtcagata	ggcctaata	ctggctttta	taatatgaga	taatgccgac	tgtacttttt	3360
acagtcggtt	ttctaattgc	actaacctgc	ccggttagtt	gaagaacgaa	gcggccgcaa	3420
ttcttgaaga	cgaaagggcc	tcgtgatacg	cctattttta	taggttaatg	tcatgataat	3480
aatggtttct	tagacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	3540
tttatttttc	taaatacatt	caaatatgta	tccgctcatg	agacaataac	cctgataaat	3600
gcttcaataa	tattgaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	3660
tccctttttt	gcggcatttt	gccttcctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	3720
aaaagatgct	gaagatcagt	tggtgtcacg	agtgggttac	atcgaactgg	atctcaacag	3780
cggtaagatc	cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttta	3840
agttctgcta	tgtggcgcg	tattatcccg	tattgacgcc	gggcaagagc	aactcggtcg	3900
ccgcatacac	tattctcaga	atgacttgg	tgagtactca	ccagtcacag	aaaagcatct	3960
tacggatggc	atgacagtaa	gagaattatg	cagtgtctcc	ataaccatga	gtgataacac	4020
tgcgccaac	ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	4080
caacatgggg	gatcatgtaa	ctgccttga	tcgttgggaa	ccggagctga	atgaagccat	4140
accaaaccgac	gagcgtgaca	ccacgatgcc	tcagcaatg	gcaacaacgt	tgcgcaaac	4200
attaactggc	gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	4260
ggataaagtt	gcaggaccac	ttctgcgctc	ggcccttccg	gctggctggg	ttattgctga	4320


```

taaactctgga gccggtgagc gtgggtctcg cggatcatt gcagcactgg ggccagatgg 4380
taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg 4440
aaatagacag atcgtcgaga taggtgcctc actgattaag catttgtaac tgtcagacca 4500
agtttactca tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta 4560
ggatgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt ttctgttcca 4620
ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg 4680
cgtaactctgc tgcttgcaaa caaaaaaacc accgctacca gcggtgggtt gtttgccgga 4740
tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa 4800
tactgtcctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc 4860
tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtctgt 4920
tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggg cgggctgaac 4980
ggggggttcg tgcacacagc ccagcttggg gcgaacgacc tacaccgaac tgagatacct 5040
acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc 5100
ggtaagcggc agggctcgaa caggagagcg cagcagggag cttccagggg gaaacgcctg 5160
gtatctttat agtctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg 5220
ctcgtcaggg gggcgagcc tatgaaaaa cgccagcaac gcggcctttt tacggttcct 5280
ggccttttgc tggccttttg ctcacatggt ctttccctcg ttatcccctg attctgtgga 5340
taaccgtatt accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg 5400
cagcagtgta gtgagcgagg aagcggaaga gcgcctgatg cggatattttc tccttacgca 5460
tctgtcggtt atttcacacc gcatactggt cactctcagt acaatctgct ctgatgccg 5520
atagtttaagc cagtatacac tccgctatcg ctacgtgact gggctcatggc tgcgccccga 5580
caccgcccaa caccgcgtga cgcgcctga cgggcttgtc tgctcccggc atccgcttac 5640
agacaagctg tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg 5700
aaacgcgcga ggcagctcgc gtaaaagctc tcagcgtggt cgtgaagcga ttacagatg 5760
tctgctgtt catccgcgtc cagctcgttg agtttctcca gaagcgttaa tgtctggctt 5820
ctgataaagc gggccatggt aagggcggtt ttttccctgt ttgtcacttg atgcctccgt 5880
gtaaggggga atttctgttc atgggggtaa tgataccgat gaaacgagag aggatgctca 5940
cgatacgggt tactgatgat gaacatgcc gggtactgga acgttgtgag ggtaacaac 6000
tggcggtatg gatgcccggg gaccagagaa aaatcactca gggtaaatgc cagcgttctg 6060
ttaatacaga tgtaggtgtt ccacagggtg gccagcagca tcctgcgatg cagatccgga 6120
acataatggt gcagggcgct gacttccgcg ttccagact ttacgaaaca cggaaaccga 6180
agaccattca tgttgttctc caggtcgcag acgttttgca gcagcagtcg cttcacgttc 6240
gctcgcgtat cggtgattca ttctgctaac cagtaaggca accccgccag cctagccggg 6300
tctcaacga caggagcagc atcatgcgca ccggtggcca ggaccaacg ctgcccaga 6360
tgcccgcggt gcgctgctg gagatggcgg acgcgatgga tatgttctgc caagggttg 6420
tttgccatt cacagtctc cgcaagaatt gattggctcc aattcttgga gtggtgaatc 6480
cgtagcgag gtgcccgcgg cttccattca ggtcgaggtg gcccggtcc atgcaccgcg 6540
acgcaacgcg gggaggcaga caaggtatag ggcggcgctt acaatccatg ccaaccggtt 6600
ccatgtgctc gccgagcgcg cataaatcgc cgtgacgatc agcgttcag tgatcgaagt 6660
taggctggta agagccgcga gcgatccttg aagctgtccc tgatggctgt catctacctg 6720
cctggacagc atggcctgca acgcgggcat cccgatgccg ccggaagcga gaagaatcat 6780
aatggggaag gccatccagc ctccgcg 6806

```

<210> 24

<211> 3867

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<400> 24

```

aagctttctc aagaagcgaa caagaaaaa gaagagcaga ttaaacagct tcaagagttt 60
gtcgtctagat tcagcgccaa tgcgtctaaa tctaagcagg ctacatcaag aaagaaactt 120
ctcgaaaaaa tcacgctgga tgatattaaa ccgtcttccc gccgtatcc ttatgttaac 180
ttcacgccgg aacgggaaat cggaaatgat gttcttccgc tggaaaggctt acaaaaaaca 240
atcgtatggcg taaagtgct tgacaatgtc agctttatta tgaatcgaga agataaaatt 300
gctttcactg gccgaaatga acttgctgtt actacgctgt ttaaatcat ttccggggaa 360
atggaagctg acagcggaac gtttaaatgg ggtgttacca catctcaagc gtattttcca 420
aaagacaaca gcgaatatct cgaaggcagt gatctgaacc ttgtagactg gcttcgcca 480

```


tattctccgc	acgaccaaag	tgagagcttt	ttacgcgggt	tcttaggacg	catgctgttc	540
tctggagaag	aagtccacaa	aaaagcaaat	gtactttccg	ggggagaaaa	ggtccgctgt	600
atgctgtcga	aagcgatgct	ttctggcgcc	aatattttaa	ttttggatga	gccgaccaac	660
catttagacc	tagagtccat	tacagcgctc	aataacggct	taatcagctt	taaaggcgct	720
atgctgttta	cttcccatga	ccatcagttt	gtgcagacca	ttgccaacag	aattatagaa	780
attacaccta	acggcatcgt	cgataagcaa	atgagctatg	acgagttcct	tgaaaatgct	840
gatgtgcaga	aaaaattgac	tgaactatac	gccgaataaa	aaagcagaga	tttctctgct	900
ttttttgata	cctaaatgtg	aaaggagatc	acaacatgaa	atttttgggt	gtcggagcag	960
gtggagtagg	cgggtatatt	ggcggacggc	tttcggagaa	aggaaatgat	gtgacatttc	1020
tcgtgcgcca	aaaacgagct	gagcagctta	aaaaaacggg	gcttgtcatc	catagtgaag	1080
aagggaatgt	atcatttcag	cccgaactaa	tcagtgcggg	agaaacaggg	caatttgatg	1140
tcgttatcat	tgcttctaaa	gcatactcgc	ttgggtcaagt	gataaggagg	gtcaaaccat	1200
ttatccatca	agaatctgtc	attatccctt	ttttaaatgg	gtaccgccac	tatgagcagc	1260
tatttgcggc	attttcaaaa	gaacaggtgc	tgggcccgtt	gtgttttata	gaaagtgtct	1320
tagacaacaa	aggagaaatt	catcatacga	gcgcatacga	tcgttttgta	tttgagagaat	1380
ggaacggcga	gcgtacggag	cggataagag	cgcttgaaga	ggcattttca	ggtgtgaagg	1440
ctgaagtcac	catttagcggg	catatcgaga	agatcccctg	cagcaatagt	tacccttatt	1500
atcaagataa	gaaagaaaag	gatttttctc	tacgctcaaa	tcctttaaaa	aaacacaaaa	1560
gaccacattt	tttaattgtg	tctttattct	tcaactaaaag	caccatttag	ttcaacaaac	1620
gaaaattgga	taaagtggga	tattttttaa	atatatatatt	atgttacagt	aatattgact	1680
tttaaaaaag	gattgattct	aatgaagaaa	gcagacaagt	aagcctccta	aattcacttt	1740
agataaaaaat	ttaggaggca	tatcaaatga	actttaataa	aattgattta	gacaattgga	1800
agagaaaaga	gatattttaat	cattatttga	accaacaaac	gacttttagt	ataaccacag	1860
aaattgatata	tagtgtttta	taccgaaaca	taaaacaaga	aggatataaa	ttttaccctg	1920
catttatattt	cttagtgaca	agggtgataa	actcaaatac	agctttttaga	actggttaca	1980
atagcgacgg	agagtttagt	tattgggata	agtttagagc	actttatata	atttttgatg	2040
gtgtatctaa	aacattctct	ggtatttggg	ctcctgtaaa	gaatgacttc	aaagagtttt	2100
atgatttata	cctttctgat	gtagagaaat	ataatggttc	ggggaaattg	tttcccaaaa	2160
cacctatacc	tgaaaatgct	ttttctcttt	ctattattcc	atggacttca	tttactgggt	2220
ttaacttaaa	tatcaataat	aatagtaatt	accttctacc	cattattaca	gcaggaaaat	2280
tcattaataa	aggtaattca	atatattttac	cgctatcttt	acaggtagat	cattctgttt	2340
gtgatgggta	tcatgcagga	ttgtttatga	actctattca	ggaattgtca	gataggccta	2400
atgactggct	ttttataat	gagataatgc	cgactgtact	ttttacagtc	ggtttttcta	2460
tggtatctaac	ctgcccgtt	agttgaagaa	ggtttttata	ttacagctcc	cgggagatct	2520
gggatcacta	gtccaaacga	cagaaggcga	ccacctgcac	ggatttttga	ttgaaaaagc	2580
aaaacgttta	tctctcgtg	caccagttat	agaaaccggt	tatgcgaatc	tgcaaatgta	2640
tgaagcagaa	aaataaaaaa	aggaggcgga	aaagcctcct	tttattttact	taaaaagccc	2700
aatttccgtt	tctgaagata	ggctctcttt	tcccgctctg	cgtaattccg	tcaatattca	2760
tatccttaga	accgatcata	aagtccacgt	gtgtaatgct	ttcatttagg	ccttctttga	2820
caagctcttc	acgagacatc	tgctttccgc	cttcaatatt	aaaggcatag	gcgcttccga	2880
tcgccaatag	atttgacgcg	ttttcatcaa	acagcgtggt	atagaaaaga	atgtttgatg	2940
gtgatatagg	cgaatcgtaa	ggaacaagtg	ccacttcacc	taaatagtga	gaaccttcac	3000
ctgtttccac	cagttctttt	aaaatatcct	cacctttttc	agctttaatg	tcgactatac	3060
ggccattttc	aaacgtcagg	gtgaaatttt	caataatatt	tccgcgtag	cttaattggt	3120
ttgtgcttga	taccactccg	tcaaccccg	ctttttgcgg	cagcgtgaac	acttcttctg	3180
tcggcatatt	ggccataaac	tcatggccac	tttcatccac	gcttcccgcg	cctgcccaca	3240
catgcttctt	aggcagctta	attgttagat	cagttccttc	tgcttgataa	tgtaaggcag	3300
cgtaatgtct	ctcgttcaaa	tgggtcaact	tttcatgaag	attttgggtc	tgattgatcc	3360
acgcctgaac	cgggttgctc	tcattttacg	gcgtcgcttt	aaaaatttct	tcccacagaa	3420
ggtggatcgc	ttcctcctct	gatttgccag	gaaacacctt	gtgagcccag	cctgctgatg	3480
ccgcacctac	gacagtccag	ctgactttgt	ctgattgaat	atattgtctg	tatgtatgta	3540
atgctttgcc	tgctgctttt	tggaaatgcc	caatccgttt	ggaatctata	ccttttagca	3600
agtctgggtt	cgacgacaca	acagaaatga	aagcagctcc	atttttggca	agctcttctc	3660
tgctttttgc	ttcccattca	ggatattctt	caaatgcttc	aaacggcgca	agttcgtatt	3720
ttaatttggc	gacttcgtca	tcttgccaat	tcacgggtgac	gttttttgcg	cccttttcat	3780
atgctgtgtt	tacaattaaa	cggacaaaat	cccgaacgtc	tgttgaagca	tttacgacta	3840
catactggcc	tttttgagaca	ttaacgc				3867

<210> 25

<211> 8704

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN238

<400> 25

```

gcgggcgctt  cgctgaccga  aacagcagtt  ataaggcatg  aagctgtccg  gtttttgcaa  60
aagtggctgt  gactgtaaaa  agaaatcgaa  aaagaccggt  ttgtgtgaaa  acggtctttt  120
tgtttccttt  taaccaactg  ccataactcg  aggcctacct  agcttccaag  aaagatatcc  180
taacagcaca  agagcggaag  gatgttttgt  tctacatcca  gaacaacctc  tgctaaaaatt  240
cctgaaaaat  tttgcaaaaa  gttgttgact  ttatctacaa  ggtgtggtat  aataatctta  300
acaacagcag  gacgctctag  aggaggagac  taacatgaaa  tttttgggtg  tcggagcagg  360
tggagtaggc  ggggtatatt  gcggacggct  ttcggagaaa  ggaaatgatg  tgacatttct  420
cgtgcgccaa  aaacgagctg  agcagcttaa  aaaaaccggg  cttgtcatcc  atagtgaaaa  480
agggaaatgta  tcatctcagc  ccgaactaat  cagtgcggga  gaaacagggc  aatttgatgt  540
cgttatcatt  gcttctaaag  catactcgct  tgggtcaagt  atagaggatg  tcaaacatt  600
tatccatcaa  gaatctgtca  ttatcccttt  tttaaatggg  taccgccact  atgagcagct  660
atctgcggca  ttttcaaaa  aacaggtgct  gggcggcctg  tggtttatag  aaagtgcctt  720
agacaacaaa  ggagaaattc  atcatacgag  cgcacgcgat  cggtttgtat  ttggagaatg  780
gaacggcgag  cgtacggagc  ggataagagc  gcttgaagag  gcattttcag  gtgtgaaggc  840
tgaagtcatc  attagcgggc  atatcgagaa  ggacatttgg  aaaaagtatc  tctttattgc  900
agcgcaagcg  gggatcacaa  cgttatttca  acgaccgctt  ggccaatcc  tcgccacaga  960
agccggacgt  cacacggccc  aaactcttat  tggggaaatt  tgactgttt  tacgaaaaga  1020
aggtgtccg  gctgatccg  ctcttgagga  agagagcttt  cgtacgatga  ccagcatgtc  1080
ttaccatatt  aagtcctcca  tgcttcggga  tatggaaaac  ggccaaacga  cagaaggcga  1140
ccacctgat  ggatttttga  ttgaaaaagc  aaaacgttta  tctctcgctg  caccagtatt  1200
agaaaccgtt  tatgcgaatc  tgcaaatgta  tgaagcagaa  aaataaaaaa  aggaggcgga  1260
aaagcctcct  tttatttact  taaaaagccc  aatttcggtt  tctgaagata  ggctctcttt  1320
tcccgctcgc  cgggacccg  ttttggcgga  tgagagaaga  ttttcagcct  gatacagatt  1380
aaatcagaac  gcagaagcgg  tctgataaaa  cagaatttgc  ctggcggcag  tagcgcggtg  1440
gtcccacctg  accccatgcc  gaactcagaa  gtgaaacgcc  gtagcgccga  tggtagtgtg  1500
gggtctcccc  atgcgagagt  agggaaactg  caggcatcaa  ataaaacgaa  aggctcagtc  1560
gaaaagactg  gcctttcgtt  ttatctgttg  tttgtcgtg  aacgctctcc  tgagttaggac  1620
aaatccgcgc  ggagcggatt  tgaacgttgc  gaagcaacgg  cccggagggt  ggcgggcagg  1680
acgcccgcga  taaaatgcca  ggcatcaaat  taagcagaag  gccatcctga  cggtggcct  1740
tttgcggttt  ctacaactc  ttggtaccga  gaaaagcgg  caaaagcggc  tgttaaaaaa  1800
gcgaaatcga  agaagctgtc  tgccgctaag  acggaatatc  aaaagcggtc  tgctgttgtg  1860
tcatctttaa  aagtcacagc  cgatgaatcc  cagcaagatg  tcctaaaata  cttgaacacc  1920
cagaagata  aaggaaatgc  agaccaaatt  cattcttatt  atgtggtgaa  cgggattgct  1980
gttcatgcct  caaaagaggt  tatggaaaaa  gtggtgcagt  ttcccgaagt  ggaaaagggt  2040
cttcctaatt  agaaacggca  gctttttaag  tcatcctccc  catttaatat  gaaaaaagca  2100
cagaagcta  ttaaagcaac  tgacgggtgt  gaatggaatg  tagaccaaat  cgatgcccc  2160
aaagcttggg  cacttgata  tgatggaact  ggcacggtt  ttgcttccat  tgataccggg  2220
gtggaatgga  atcatccggc  attaaaagag  aaatctcgcg  gatataatcc  ggaaatcct  2280
aatgagcctg  aaaatgaaat  gaactggtat  gatgccgtag  caggcgaggc  aagcccttat  2340
gatgatttgg  ctcatggaac  ccacgtgaca  ggcacgatgg  tgggctctga  acctgatgga  2400
acaaatcaaa  tcggtgtagc  acctggcgca  aaatggattg  ctgttaaagc  gttctctgaa  2460
gatggcggca  ctgatgctga  catcttgtaa  gctggtgaat  gggttttagc  accaaaggac  2520
gcggaaggaa  atccccacc  ggaaatggct  cctgatgttg  tcaataactc  atggggaggg  2580
ggctctggac  ttgatgaatg  gtacagagac  atggtcaatg  cctggcggtc  ggccgatatt  2640
ttccctgagt  tttcagcggg  gaatacggat  ctctttatc  ccggcgggcc  tggttctatc  2700
gcaaatccg  caaactatcc  agaactcgtt  gcaactggag  cgactgagaa  ttccaattcc  2760
ccatggagag  aaaagaaaat  cgctaattgt  gattactttg  aacttctgca  tattcttgaa  2820
tttaaaaagg  ctgaaagagt  aaaagattgt  gctgaaatat  tagagtataa  acaaaatcgt  2880

```

gaaacaggcg	aaagaaagtt	gtatcgagtg	tggttttgta	aatccaggct	ttgtccaatg	2940
tgcaactgga	ggagagcaat	gaaacatggc	attcagtcac	aaaagggttg	tgctgaagtt	3000
attaacaaca	agccaacagt	tcgttggttg	tttctcacat	taacagttaa	aaatgtttat	3060
gatggcgaag	aattaaataa	gagttttgca	gatatggctc	aaggatttcg	ccgaatgatg	3120
caatataaaa	aaattaataa	aaatcttggt	ggttttatgc	gtgcaacgga	agtgacaata	3180
aataataaag	ataattctta	taatcagcac	atgcatgtat	tggtatgtgt	ggaaccaact	3240
tattttaaga	atacagaaaa	ctacgtgaat	caaaaacaat	ggattcaatt	ttggaaaaag	3300
gcaatgaaat	tagactatga	tccaaatgta	aaagttcaaa	tgattcgacc	gaaaaataaa	3360
tataaatcgg	atatacaatc	ggcaattgac	gaaactgcaa	aatatcctgt	aaaggatacg	3420
gattttatga	ccgatgatga	agaaaagaat	ttgaaacggt	tgtctgattt	ggaggaaggt	3480
ttacaccgta	aaaggttaat	ctcctatggg	ggtttggtta	aagaaataca	taaaaaatta	3540
aaccttgatg	acacagaaga	agggcatttg	attcatacag	atgatgacga	aaaagccgat	3600
gaagatggat	tttctattat	tgcaatgtgg	aattgggaac	ggaaaaatta	ttttattaaa	3660
gagtagttca	acaaacgggc	catattgttg	tataagtgat	gaaatactga	atttaaaact	3720
tagtttata	gtggtaaaat	gttttaatca	agtttaggag	gaattaatta	tgaagtgtaa	3780
tgaatgtaac	agggttcaat	taaaagaggg	aagcgtatca	ttaaccctat	aaactacgtc	3840
tgccctcatt	attggagggt	gaaatgtgaa	tacatcctat	tcacaatcga	atttacgaca	3900
caaccaaatt	ttaatttggc	tttgcatttt	atcttttttt	agcgtattaa	atgaaatggg	3960
tttgaacgtc	tcattacctg	atattgcaaa	tgattttaat	aaaccacctg	cgagtacaaa	4020
ctgggtgaac	acagccttta	tgtaaacctt	ttccattgga	acagctgtat	atggaaagct	4080
atctgatcaa	ttaggcatca	aaaggttact	cctatttggg	attataataa	attgtttcgg	4140
gtcggtaatt	gggtttgttg	gccattcttt	cttttcctta	cttattatgg	ctcgttttat	4200
tcaaggggct	ggtgcagctg	catttccagc	actcgtaatg	gttgtagttg	cgcgctatat	4260
tccaaaggaa	aataggggta	aagcatttgg	tcttattgga	tcgatagtag	ccatgggaga	4320
aggagtcggg	ccagcgattg	gtggaatgat	agcccattat	attcattggg	cctatcttct	4380
actcattcct	atgataacaa	ttatcactgt	tccgtttcct	atgaaattat	taaagaaaga	4440
agtaaggata	aaaggtcatt	ttgatatcaa	aggaattata	ctaagtctctg	taggcattgt	4500
attttttatg	ttgttttaca	catcatatag	catttctttt	cttatcggtta	gcgtgctgtc	4560
attcctgata	tttgtaaaac	atatcaggaa	agtaacagat	ccttttggtg	atcccggatt	4620
agggaaaaat	atacctttta	tgattggagt	tctttgtggg	ggaattatat	ttggaacagt	4680
agcagggttt	gtctctatgg	ttccttatat	gatgaaagat	gttcaccagc	taagtactgc	4740
cgaaatcgga	agtgtaaata	ttttccctgg	aacaatgagt	gtcattatatt	tcggctacat	4800
tggtgggata	cttggtgata	gaagagggtc	tttatacgtg	ttaaacatcg	gagttacatt	4860
tctttctggt	agctttttta	ctgcttcctt	tcttttagaa	acaacatcat	ggttcatgac	4920
aattataatc	tgatttgggt	taggtgggct	ttcgttcacc	aaaacagtta	tatcaacaat	4980
tgtttcaagt	agcttgaaac	agcaggaagc	tggtgctgga	atgagtttgc	ttaaactttac	5040
cagcttttta	tcagagggaa	caggtattgc	aattgtaggt	ggtttattat	ccataccctt	5100
acttgatcaa	aggttggttac	ctatggaagt	tgatcagtc	acttatctgt	atagtaattt	5160
gttattactt	ttttcaggaa	tcatgtcat	tagttggctg	gttaccttga	atgtatataa	5220
acatttctca	agggatctt	aaatcgttaa	gggatcaact	ttgggagaga	gttcaaaatt	5280
gatccttttt	ttataacagt	tcgaagcggc	cgcaattcct	gaagacgaaa	gggcctcgtg	5340
atacgcctat	tttatagggt	taatgtcatg	ataataatgg	tttcttagac	gtcaggtggc	5400
acttttcggg	gaaatgtgcg	cggaaccctt	atgtgtttat	ttttctaaat	acattcaaat	5460
atgtatccgc	tcatgagaca	ataaccctga	taaatgcttc	aataatattg	aaaaaggaag	5520
agtatgagta	ttcaacattt	ccgtgtcgcc	cttatccctt	tttttgcggc	attttgcctt	5580
cctgtttttg	ctcaccagaa	aacgctgggt	aaagtaaaag	atgctgaaga	tcagttgggt	5640
gcacgagtg	gttacatcga	actggatctc	aacagcggt	agatccttga	gagttttcgc	5700
cccgaagaac	gttttccaat	gatgagcaat	tttaaagttc	tgctatgtgg	cgcggtatta	5760
tcccgatttg	acgccgggca	agagcaactc	ggtcgccgca	tacactattc	tcagaatgac	5820
ttggttgagt	actcaccagt	cacagaaaag	catcttacgg	atggcatgac	agtaagagaa	5880
ttatgcagtg	ctgccataac	catgagtgat	aacactgcgg	ccaacttact	tctgacaacg	5940
atcggaggac	cgaaggagct	aaccgctttt	ttgcacaaca	tgggggatca	tgtaactcgc	6000
cttgatcggt	gggaaccgga	gctgaatgaa	gccataccaa	acgacgagcg	tgacaccacg	6060
atgcctgcag	caatggcaac	aacgttgcgc	aaactattaa	ctggcgaact	acttactcta	6120
gcttcccggc	aaacaattaat	agactggatg	gaggcggata	aagttgcagg	accacttctg	6180
cgctcggccc	ttccggctgg	ctggtttatt	gctgataaat	ctggagccgg	tgagcgtggg	6240
tctcgggta	tcattgcagc	actggggcca	gatggtaagc	cctcccgtat	cgtagttatc	6300
tacacgacgg	ggagtccagg	aactatggat	gaacgaaata	gacgatcgc	tgagataggt	6360
gcctcactga	tttaagcattg	gtaactgtca	gaccaagttt	actcatatat	acttttagatt	6420
gatttaaaac	ttcatTTTTA	atTTaaaagg	atctaggtga	agatcctttt	tgataatctc	6480

```

atgaccaaaa tcccttaacg tgagtttttcg ttccactgag cgtcagaccc cgtagaaaaag 6540
atcaaaggat cttcttgaga tccctttttt ctgcgcgtaa tctgctgctt gcaaacaaaa 6600
aaaccacgcg taccagcgtt gggtttgttg cgggatcaag agctaccaac tctttttccg 6660
aaggtaaactg gcttcagcag agcgcagata ccaaatactg tcccttctagt gtagccgtag 6720
ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatacctg 6780
ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga 6840
tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gtctgtgcac acagcccagc 6900
ttggagcgaa cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc 6960
acgcttcccg aagggagaaa ggcgacagc tatccggtaa gcggcagggc cggaacagga 7020
gagcgacga gggagcttcc agggggaaac gcctggatc tttatagtcc tgtcgggttt 7080
cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggag gagcctatgg 7140
aaaaacgcca gcaacgcggc ctttttacgg ttccctggcct tttgctggcc ttttgctcac 7200
atgttctttc ctgctttatc ccctgattct gtggataacc gtattaccgc ctttgagtga 7260
gctgataccg ctgcgcgag ccgaacgacc gagcgagcg agtcagttag cgaggaagcg 7320
gaagagcgcc tgatgcggtt tttctcctt acgcctctgt gcggtatttc acaccgcata 7380
tggtgcactc tcagtacaat ctgctctgat gccgcatagt taagccagta tacactccgc 7440
tatcgctaag tgactgggtc atggctgcgc ccgcacaccc gccaacaccc gctgacgcgc 7500
cctgacgggc ttgtctgctc ccggcatccg cttacagaca agctgtgacc gtctccggga 7560
gctgcatgtg tcagagggtt tcacgctcat caccgaaacg cgcgaggcag ctgcggtaaa 7620
gctcatcagc gtggctcgtg agcgattcac agatgtctgc ctgttcatcc gcgtccagct 7680
cggttagttt ctccagaagc gttaatgtct ggcttctgat aaagcgggcc atgttaaggg 7740
cggttttttc ctgtttggtc acttgatgcc tccgtgtaag ggggaatttc tgttcatggg 7800
ggtaatgata ccgatgaaac gagagaggat gctcacgata cgggttactg atgatgaaca 7860
tgcccggtta ctggaacggt gtgagggtaa acaactggcg gtatggatgc ggcgggacca 7920
gagaaaaatc actcagggtc aatgccagcg cttcgttaat acagatgtag gtgttccaca 7980
gggtagccag cagcatcctg cgatgcagat ccggaacata atggtgcagg gcgtgactt 8040
ccgcgttttc agactttacg aaacacggaa accgaagacc attcatgttg ttgctcaggt 8100
cgcagacggt ttgcagcagc agtcgcttca cgttcgctcg cgtatcgggtg attcattctg 8160
ctaaccagta aggcaacccc gccagcctag ccgggtcctc aacgacagga gcacgatcat 8220
gcgcaccggt ggccaggacc caacgctgcc cgagatgcgc cgcgtgcggc tgctggagat 8280
ggcgagcgcg atggatatgt tctgccaaag gtggttttgc gcattcacag ttctccgcaa 8340
gaattgattg gctccaattc ttggagtggg gaatccgtta gcgaggtgcc gccggcttcc 8400
attcagggtc aggtggcccg gctccatgca ccgcgacgca acgcggggag gcagacaagg 8460
tatagggcgg cgcctacaat ccatgccaac cgttccatg tgctcgccga ggcggcataa 8520
atcgccgtga cgatcagcgg tccagtgtat gaagttaggc tggtaagagc cgcgagcgat 8580
cctgaagct gtccctgatg gtgctcatct acctgcctgg acagcatggc ctgcaacgcg 8640
ggcatcccga tgccgccgga agcgagaaga atcataatgg ggaaggccat ccagcctcgc 8700
gtcg 8704

```

<210> 26

<211> 6688

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN336

<400> 26

```

tgccgcgcta cagggcgcggt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttcccag tcacgacggt gtaaaacgac ggccagtga 180
ttgtaatacg actcactata gggcgaattg ggcccacgct cgcattgcac aggttcttca 240
ggcgctgact tagaaaaacct cttgaatgaa gctgcgcttg tagcggtcgc tcaaaacaag 300
aaaaaaatcg atgcgcgtga tattgacgaa gcgacggacc gtgtaattgc cggacccgct 360
aagaagagcc gcgttatctc caagaaagaa cgcaatatcg tggcttatca cgaaggcgga 420
cacaccgtta tcggtctcgt tttagatgag gcagatatgg ttcataaagt aacgattggt 480

```

cctcgggggc	aggctggcgg	ttatgctgtt	atgctgccaa	gagaagaccg	ttattttcaa	540
acaaagccgg	agctgcttga	taaaattgtc	ggcctcttgg	gcggacgtgt	tgctgaagag	600
attatcttcg	gtgaagtacg	cacaggggcg	cacaatgact	tccagcgtgc	gacgaatatt	660
gcaagacgaa	tggttacaga	attcgggtatg	tcagaaaaaac	tgggaccggt	gcaatttggg	720
cagtctcagg	gcggtcaggt	attccttaggc	cgtgatttca	acaacgaaca	gaactacagt	780
gatcaaatcg	cttacgaaat	tgatcaggaa	attcagcgca	tcatacaaga	atgttatgag	840
cgtgcgaaac	aaatcctgac	tgaaaatcgt	gacaagcttg	aattgattgc	ccaaacgctt	900
ctgaaagttg	aaacgcttga	cgtcgaacaa	atcaaacacc	ttatcgatca	tggaaacatta	960
cctgagcgta	atttctcaga	tgatgaaaag	aacgatgatg	tgaaagtaaa	cattctgaca	1020
aaaaacagaag	aaaagaaaaga	cgatacgaag	gagtaattcg	ctttctttct	aaaaaaactg	1080
ccggctgacg	ctggcagttt	ttttatgtaa	atgattggct	cagctgcggc	ttttacaact	1140
atccaattct	ggatcagatt	tgtttacaaa	tgagccgctg	atcgtgtatg	gtattgtaga	1200
atgtttgtaa	aaagtaaaag	agagaaaacta	ttcaaaaagt	gtgatagagg	ttgttactgg	1260
ttatcgatgt	ggggaacacc	ctgcagctcg	agtgaataac	cgcacagatg	cgtaaggaga	1320
aaataccgca	tcaggcgata	aaccacgca	accatttgag	gtgataggta	agattatacc	1380
gaggtatgaa	aacgagaatt	ggacctttac	agaattactc	tatgaagcgc	catattttaa	1440
aagctaccaa	gacgaagagg	atgaagagga	tgaggaggca	gattgccttg	aatatattga	1500
caatactgat	aagataatat	atcttttata	tagaagatat	cgcctgatgt	aaggatttca	1560
gggggcaagg	cataggcagc	gcgcttatca	atatactat	agaatgggca	aagcataaaa	1620
acttgcattg	actaatgctt	gaaacccagc	acaataacct	tatagcttgt	aaattctatc	1680
ataattgttg	tttcaaaatc	ggctccgtcg	atactatgtt	atacgccaac	tttcaaaaac	1740
actttgaaaa	agctgttttc	tggattttta	ggttttagaa	tgcaaggaaac	agtgaatttg	1800
agttcgtctt	gttataatta	gcttcttggg	gtatctttaa	atactgtaga	aaagagggaag	1860
gaaataataa	atggctaaaa	tgagaatata	accggaattg	aaaaaactga	tcgaaaaata	1920
ccgtgcgta	aaagatacgg	aaggaatgtc	tcctgctaag	gtatataaag	tgggtgggaga	1980
aaatgaaaaa	ctatatttta	aaatgacgga	cagccggtat	aaagggacca	cctatgatgt	2040
ggaacgggaa	aaggacatga	tgctatggct	ggaaggaaag	ctgcctgttc	caaaggtcct	2100
gcactttgaa	cggcatgatg	gctggagcaa	tctgctcatg	agtgaggccg	atggcgctct	2160
ttgctcgga	gagtatgaag	atgaacaaag	ccctgaaaag	attatcgagc	tgtatgcgga	2220
gtgcatcagg	ctctttcact	ccatcgacat	atcggattgt	ccctatacga	atagcttaga	2280
cagccgctta	gccgaatttg	attacttact	gaataacgat	ctggccgatg	tggattgcga	2340
aaactgggaa	gaagacactc	cattttaaaga	tcgcgcgag	ctgtatgatt	ttttaaaagac	2400
ggaaaagccc	gaagaggaac	ttgtcttttc	ccacggcgac	ctgggagaca	gcaacatctt	2460
tgtgaaagat	ggcaaaagta	gtggctttat	tgatcttggg	agaagcggca	gggaggacaa	2520
gtggtatgac	attgccttct	gcgtccggtc	gtacaggag	gatatacggg	aagaacagta	2580
tgctcagcta	ttttttgact	tactggggat	caagcctgat	tgggagaaaa	taaaatatta	2640
tattttactg	gatgaattgt	tttagtacct	agatttagat	gtctaaaaag	ctttaactac	2700
aagcttttta	gacatctaata	cttttctgaa	gtacatccgc	aactgtccat	actctgatgt	2760
tttatatctt	ttctaaaaag	tcgctagata	ggggtcccga	gcgcctacga	ggaatttgta	2820
tcgccattcg	ccattcaggc	tgcgcaactg	ttgggaaggg	cgatcgggtc	ggtcgactgg	2880
caggcaaaac	aggaccaag	gtcattgcga	caggaggcct	ggcgccgctc	attgcgaacg	2940
aatcagattg	tatagacatc	gttgatccat	tcttaaccct	aaaagggctg	gaattgattt	3000
atgaaagaaa	ccgcgtagga	agtgtatagg	aggtttagta	atggattatt	tagtaaaagc	3060
acttgcgtat	gacggaaaaag	ttcgggctta	tgacgagaga	acgactgata	tggtaaatga	3120
ggggcagaga	cgccatggta	cgtggccgac	agcatccgct	gcactaggcc	gtacaatgac	3180
agcttcactt	atgctcggcg	ctatgctgaa	gggcgatgat	aagctgaccg	tgaaaatcga	3240
gggcggaggt	ccgatcggag	ctattgtagc	tgatgccaat	gccaaaggag	aagtcagagc	3300
ctatgtctct	aacccgcaag	ttcattttga	tttaaatgaa	caaggtaagc	ttgatgtcag	3360
acgtgcgggt	ggaacaaacg	gaacgttaag	tgtcgtaaaa	gatttaggtt	tgcgcgagtt	3420
cttcacagga	caagtagaaa	tcgtttcagg	agaattagga	gatgatttta	cttactatct	3480
tgtgtcatct	gagcaggttc	cttcacagct	gggcgtaggt	gtgctcgtaa	atcctgacaa	3540
taccattctt	gcggcagggg	gctttattat	tcagctgatg	ccgggaacag	atgatgaaac	3600
aatcacaaaa	attgaacagc	gtctatctca	agtagagccg	atttctaagc	tcatacaaaa	3660
agggctgaca	ccagaagaaa	ttttagaaga	agtcctaggc	gagaaacctg	agatttttgg	3720
aacgatgcct	gtcagattcc	attgcccttg	ttcaaaaagaa	cggttcgaaa	cagccatttt	3780
aggactaggc	aaaaaagaaa	ttcaagatat	gatagaagaa	gatggacaag	ccgaagcagt	3840
atgccatttt	tgtaatgaaa	agtacttatt	tacaaaagaa	gagctggaag	ggcttcgtga	3900
ccaaactacc	cgtaaagctc	tttagcgggt	ttttaatttg	agaaaagggg	ctgaaagcag	3960
gtttgaaatc	aagaacaatc	tggacgcgtt	ggatgcatag	cttgagtatt	ctatagtgtc	4020
acctaataag	cttggcgtaa	tcattggtcat	agctgtttcc	tgtgtgaaat	tgttatccgc	4080

```

tcacaattcc acacaacata cgagccggaa gcataaagt taaagcctgg ggtgcctaata 4140
gagttagctta actcacatta attgcgttgc gctcactgcc cgctttccag tcgggaaacc 4200
tgctcgtagca gctgcattaa tgaatcgccc aacgcgcggg gagaggcggg ttgcgtattg 4260
ggcgtctctc cgcttccctc ctcactgact cgctgcgtc ggctcgttcg ctgcggcgag 4320
cggtagcagc tcaactcaaag gcggtaatac ggtagtccac agaatacagg gataacgcag 4380
gaaagaacat gtgagcaaaa ggccagcaaa aggcagagaa ccgtaaaaaa gccgcgttgc 4440
tgccgttttt cgataggctc cgccccctg acgagcatca caaaaatcga cgctcaagtc 4500
agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc 4560
tcgtgcgtc tcctgttccg accctgccgc ttaccggata cctgtccgcc tttctccctt 4620
cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg 4680
ttcgctccaa gctgggctgt gtgcacgaac ccccggttca gcccgaccgc tgcgccttat 4740
ccggtaaacta tcgtcttgag tccaaccgg taagacacga cttatcgcca ctggcagcag 4800
ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaagt 4860
ggtaggcctaa ctacggctac actagaagga cagtatttgg tatctgcgt ctgctgaagc 4920
cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaacc accgctggta 4980
gcggtggttt ttttgttgc aagcagcaga ttacgcgcag aaaaaagga tctcaagaag 5040
atcctttgat cttttctacg gggctctgac ctcagtggaa cgaaaactca cgtaaggga 5100
ttttggtcat gagattatca aaaaggatct tcacctagat ctttttaaat taaaaatgaa 5160
gttttaaatc aatctaaagt atatatgagt aaacttggc tgacagttac caatgcttaa 5220
tcagtgggc acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc 5280
ccgtcgtgta gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga 5340
taccgcgaga cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa 5400
gggcccagcg cagaagtggc cctgcaactt tatccgcctc catccagtct attaatgtt 5460
gccgggaagc tagagtaagt agttcgccag ttaatagttt gcgcaacgtt gttggcattg 5520
ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcatcagc tccggttccc 5580
aacgatcaag gcgagttaca tgatcccca tgggttgcaa aaaagcgggt agctccttcg 5640
gtcctccgat cgttctcaga agtaagtgg ccgcagtgtt atcactcatg gttatggcag 5700
cactgcataa ttctcttact gtcatgccat ccgtaagatg cttttctgtg actggtgagt 5760
actcaacca gtcattctga gaataccgcg cccggcgacc gagttgctct tgccccgcgt 5820
caatacggga taatagtgtg tgacatagca gaactttaa agtgctcatc attggaaaac 5880
gttcttcggg gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac 5940
ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag 6000
caaaaacagg aaggcaaaat gccgcaaaaa aggggaataa ggcgacacgg aaatgttgaa 6060
tactcatact cttctctttt caatattatt gaagcattta tcagggttat tgtctcatga 6120
gcgatacat atttgaatgt atttgaaaa ataaacaaat aggggttccg cgcacatttc 6180
cccgaagaat gccacctgta tgcggtgtga aataccgcac agatgcgtaa ggagaaaata 6240
ccgcatcagg cgaaattgta aacgttaata ttttgttaa attcgcgtta aatatttgtt 6300
aaatcagctc attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaa 6360
aatagaccga gatagggttg agtggtgttc cagtttgtaa caagagtcca ctattaaaga 6420
acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6480
aacatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6540
ctaaagggag cccccgatt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6600
aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6660
gcgtaaccac cacaccgcc gcgcttaa 6688

```

<210> 27

<211> 8803

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector

<220>

<223> pAN294

<400> 27

```

tgccgcgcta cagggcgcggt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcgggtcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagtggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac ggccagtga 180

```

ttgtaatacg	actcactata	gggcgaattg	ggcccgacgt	cgcattgctgg	atgaaaagcc	240
gatgaccgct	tttcaggctct	gtcagcagct	ttttcctgct	gtatatgaaa	aggaattgtt	300
tttaacgatg	tcagaaacgg	caggtcacct	tgatgtgttg	gaggctgaag	aagccatcac	360
gtcatattgg	gaaggaaata	ccgtatactt	taaaacaatg	aagagggtgaa	atgggtgaaa	420
catatagcgg	gaaaaaggat	ttggataacc	ggcgcttcag	gagggttg	agaaagaatc	480
gcatacttat	gcgcggctga	aggagcccat	gtcctgctgt	cggctagacg	cgaggatcgt	540
ttgatagaaa	tcaaaaggaa	aataaccgag	gaatggagcg	gacagtgtga	gatttttccct	600
ctggatgtcg	gccgcctaga	ggatatcgcc	cgggtccgcg	atcagatcgg	ctcgattgat	660
gtactgatta	acaatgcagg	cttcgggtata	tttgaaacgg	tttttagactc	tacattggat	720
gacatgaaa	cgatgtttga	tgtgaatgtc	ttcggcctga	tcgcctgtac	aaaagcgggtg	780
cttcgcgaaa	tgcttgagca	aaaaaaggga	catatcatca	atatcgccctc	tcaagcgggg	840
aaaatcgcca	caccgaagtc	tagcctgtat	tccgcgacca	aacatgccgt	gttaggttac	900
tcaaaccttat	tgcggatgga	gcttttcggga	accggcattt	atgtgacaac	agtcaaccgg	960
ggcccgattc	agacggactt	tttttccatt	gctgataaag	gcggggacta	cgccaaaaat	1020
gtcggccgct	ggatgcttga	tcttgatgac	gtggcagctc	aaattacagc	tgcaattttt	1080
acgaaaaagc	gggagatcaa	tcttcgcgct	ttaatgaatg	ccggcactaa	gctgtatcag	1140
ctgtttccag	ctcttgtaga	aaagctggca	ggacgcgcgc	tcatgaaaaa	ataatgatag	1200
aactgcctgt	ggtggagtgg	cttggtttctc	acggggcag	ttttgatagt	ggaagggaga	1260
gattgttgaa	tgtcagttca	ttcagaagtc	cttcagctc	tgcttaaaga	tccgtttatt	1320
cagaaactga	ttgatgcaga	gcctgtatct	tgggcaaat	caggcaagaa	agaggggcca	1380
ttaccccggtg	cgatgagtg	ggcaaccgag	atagcggaag	cggaaaaaag	aatgcagcgg	1440
tttgacactt	acattgccga	ggtgtttcct	gagacgaaag	gcgctaagag	aatcatcgag	1500
tctccgcttt	ttgaggtgca	gcataatgaag	ggaaagctgg	aagcggcata	tcagcagcca	1560
tttcccgga	gatggctttt	aaagtgcgac	catgagcttc	cgatttcagg	atcgattaaa	1620
gcgagggcg	ggatttatga	agtgttaaag	tatgctgaaa	atctcgcgct	tcaagaagga	1680
atgcttcagg	aaaccgatga	ttaccgcctc	ttacaggaag	agcggtttac	cgggtttttc	1740
tcccgctatt	cgattgtctgt	cggttcgaca	ggaaatctag	gtttaagcat	cgcatcctc	1800
ggcgccgac	tcgggtttcg	cgtgacagtg	catatgtccg	cgatgctaa	gcagtggaaa	1860
aaggatctcc	tccgccaaaa	gggagtcact	gttatggagt	acgaaacaga	ttacagtga	1920
gcggtgaacg	aaggagagacg	gcaggcggaa	caagatccat	tctgttattt	tattgatgat	1980
gaacattctc	gtcagctgtt	cttaggatat	gctgttgctg	caagccgatt	aaaaacacag	2040
cttgactgta	tgaatataaa	gccaaagtctt	gagacgccct	tgtttggtga	tctgccgtgc	2100
ggagtcggcg	gaggaccggg	cgggtgtagca	tttgggtga	agctttttata	cggagatgat	2160
gttcattgtgt	ttttcgcaga	accaactcat	tcacctgtga	tgctgttagg	gctttattca	2220
ggacttcacg	agaaggatctc	cgtccaggat	atcggcctgg	ataatcagac	ggctgctgac	2280
ggacttgccg	tagggaggcc	gtcaggattt	gtcggcaagc	tgattgaacc	gcttctgagc	2340
ggctgttata	cggtagagga	caatacgtct	tatactttgc	ttcatatgct	ggctgtatct	2400
gaagataaat	atthagagcc	ctctgctctt	gctggcatgt	tcgggcccgt	tcagcttttt	2460
tcgacagaag	agggaaaggcg	ctatgctcag	aaatataaga	tggaacatgc	cgtacatgtc	2520
gtctggggaa	cgggaggaag	catggttcca	aaagatgaaa	tggtgcgta	taaccgaatc	2580
ggtgctgatt	tgctaaaaaa	acgaaatgga	aaataagcag	acagtgaaaa	ggttttccgt	2640
tacaactctt	gtaagggttt	taacctacag	agagtcagg	gtaaacagtg	aaaaataaag	2700
aatctaacct	acatacttta	tatacacagc	acaatcggga	gtcttggtct	ggttttggg	2760
ggcatttgtc	gattgctgta	tctgaagaag	aggcaaaagc	tgtggaagga	ttgaatgatt	2820
atctatctgt	tgaagaagtg	gagacgatct	atattccgct	tgttcgcttg	cttcattttac	2880
atgtcaagtc	tcgggctgaa	cgcaataagc	atgtcaatgt	ttttttgaag	caccacatt	2940
cagccaaaat	tccgtttatt	atcggcattg	cggcagtggt	cgcagtcgga	aaaagcacga	3000
cggcgcgat	cttgacagaag	ctgctttcgc	gtttgcctga	ccgtccaaaa	gtgagcctta	3060
tcacgacaga	tggtttttta	tttcctactg	ccgagctgaa	aaagaaaaat	atgatgtcaa	3120
gaaaaggatt	tcctgaaagc	tatgatgtaa	aggcgctgct	cgaatttttg	aatgacttaa	3180
aatcaggaaa	ggacagcgta	aaggccccgg	tgtattccca	tctaacctat	gaccgcgagg	3240
aagggtgtgt	cgagggttga	gaacaggcgg	atattgtgat	tattgaaggc	attaatgttc	3300
ttcagtcgcc	caccttgag	gatgaccggg	aaaaccgcg	tatttttgtt	tccgattttc	3360
ttgatttttc	gatttatgtg	gatgcggagg	aaagccggat	tttcacttgg	tatttagagc	3420
gttttcgcct	gcttcgggaa	acagcttttc	aaaatcctga	ttcatatttt	cataaattta	3480
aagacttgtc	cgatcaggag	gctgacgaga	tggcagcctc	gatttgggag	agtgtcaacc	3540
ggccgaattt	atatgaaaat	attttgccaa	ctaaattcag	gtcagatctc	attttgcgta	3600
agggagacgg	gcataaggctc	gaggaaagtg	ggtaaggag	ggtatgaaat	gtgctgcagc	3660
tcgagcaata	gttaccctta	ttatcaagat	aagaaagaaa	aggatttttc	gctacgctca	3720
aatcctttta	aaaaacacaa	aagaccacat	tttttaatgt	ggtctttatt	cttcaactaa	3780

agcaccatt	agttcaacaa	acgaaaattg	gataaagtgg	gatattttta	aaatatatat	3840
ttatgttaca	gtaaatattga	cttttaaaaa	aggattgatt	ctaatagaaga	aagcagacaa	3900
gtaagcctcc	taaatctact	ttagataaaa	athtagagg	catatcaa	gaacttta	3960
aaaattgatt	tagacaattg	gaagagaaaa	gagatattta	atcattat	gaaccaacaa	4020
acgactttta	gtataaccac	agaaattgat	attagtgttt	tataccgaaa	cataaaacaa	4080
gaaggatata	aattttaccc	tgcattttatt	ttcttagtga	caaggggtgat	aaactcaaat	4140
acagctttta	gaactgggta	caatagcgac	ggagagttag	gttattggga	taagttagag	4200
ccactttata	caatttttga	tggtgtatct	aaaacattct	ctgggtattg	gactcctgta	4260
aagaatgact	tcaaagagtt	ttatgattta	tacctttctg	atgtagagaa	atataatggt	4320
tcggggaaat	tgtttcccaa	aacacctata	cctgaaaatg	ctttttctct	ttctattatt	4380
ccattgactt	catttactgg	gtttaactta	aatatcaata	ataatagtaa	ttaccttcta	4440
ccatttatta	cagcaggaaa	attcattaat	aaaggtaatt	caatataatt	accgctatct	4500
ttacagggtac	atcattctgt	ttgtgatggt	tatcatgcag	gattgtttat	gaactctatt	4560
caggaattgt	cagataggcc	taatgactgg	cttttataat	atgagataat	gccgactgta	4620
ctttttacag	tcggttttct	aatgtcacta	acctgccccg	ttagttgaag	aagggtttta	4680
tattacagct	gtcgactcgt	gatcttcgga	caggctgttc	agctttttct	caatgcgatc	4740
cagctgcgct	ttcgggtttt	tcgcatactt	gaagcctgta	acagccgcaa	agacgacagc	4800
ggcaaatata	ataaatataa	acagctgaaa	catcacatca	cctatattca	tggtcttcac	4860
ctcatgtttg	cgggagagat	tcattctctt	ccgtttttta	tttaaagcgg	cttttccaga	4920
cgggaacggg	gttttgtggt	ctccattttc	atttgccgat	aggcgaacgc	taaaaatggc	4980
aggccgagca	gggtaatgcc	gctcaggaca	gaaaaaatat	aaatcggccg	gccagcgcca	5040
aacaggctta	tacatatccc	cccgaaccaa	gggccgatga	cgtttccgag	ctgtggaaaa	5100
ccgattgccc	cgaaataagt	gcctttta	cctgggtttg	caatctggtc	tacatacaaa	5160
tccatcatag	agaataaaa	cacttcgccg	attgtaaatg	tgatgacaat	catcacaatt	5220
gatggaacac	cgtgtgatac	ggtgaaaatg	gccatgctga	tgctaaccat	cacattaccg	5280
agcatcagag	aacaaagcgg	cgaaaaccgt	tttgcaaaat	ggacaatggg	aaattgcgct	5340
gccaacacaa	cgattgcgtt	taatgtcagc	atcagcccat	acagcttcgt	tccattgccc	5400
atcaaggggt	tctgcgccat	atactgaggg	aatgtggaac	tgaattgtga	gtagccgaag	5460
gtgcatagcg	taatgccgac	caaagcaatg	gtaaaaagat	aatccttttg	cgtgaccata	5520
aacgcttccc	gcacgctcat	atctcgggac	tgggctggtg	ctgataagga	tggatgtttt	5580
ttaaattgga	gggcaagcac	aattccgtat	agtccgtaaa	tgactgcagg	cacaaaaaag	5640
ggcgtagtcg	attgcgatga	gccgaaatat	aggccaagca	caggctcgga	gacaacgcgg	5700
atattaatag	ccgcatagcg	taaattaaaa	actagcagtc	tcgttttttc	ttctgtcata	5760
tcagatacag	aggcctttga	agcgggctca	aacagtgatt	tgcaaagacc	gtttaatgct	5820
tttactacaa	aaaacaccca	gagattagat	gctgccgcaa	agcctgcaaa	taccagcatc	5880
catccgaaaa	tcgatacaag	catcatgttt	tttctgccga	atctatctga	gatatatccg	5940
ccgtaaaagc	ttgcgaggat	gccgactgat	gagctcgcgg	cgatgaccag	ccctgcatag	6000
gaagctgatg	cgcttgggac	ggctgtcaaa	taaatacgta	aaaaaggaat	gctcatcgat	6060
gttgccattc	tgccgaaaa	ggttccgatt	ataattgtac	gcgttggtatg	catagcttga	6120
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttctgtgtg	6180
gaaattgtta	tccgctcaca	attccacaca	acatacagac	cggaagcata	aagtgtaaag	6240
cctggggtgc	ctaatgagtg	agctaactca	cattaattgc	gttgcgctca	ctgcccgctt	6300
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	6360
gcggtttgcg	tattggggcg	tcttcgctt	cctcgctcac	tgactcgctg	cgctcggtcg	6420
ttcggtcgcg	gcgagcggta	tcagctcact	caaaggcggt	aatacggtta	tccacagaat	6480
caggggataa	cgagggaaag	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta	6540
aaaaggccgc	gttgctggcg	tttttcgata	ggctccgccc	ccctgacgag	catcacaana	6600
atcgacgctc	aagtcagagg	tgccgaaaacc	cgacaggact	ataaagatac	caggcggttc	6660
cccctggaag	ctccctcgtg	cgctctcctg	ttccgaccct	gccgcttacc	ggatacctgt	6720
ccgcttttct	cccttcggga	agcgtggcgc	tttctcatag	ctcacgctgt	aggatatcta	6780
gttcggtgta	ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagcccc	6840
accgctgcgc	cttatccggt	aactatcgtc	ttgagtccaa	cccggttaaga	cacgacttat	6900
cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gagggtatgta	ggcgggtgcta	6960
cagagttctt	gaagtgggtg	cctaactacg	gctacactag	aaggacagta	tttggtatct	7020
gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	7080
aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaagca	gcagattacg	cgcaaaaaaa	7140
aagatctcta	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag	tggaacgaaa	7200
actcagctta	agggtttttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	7260
taaattaaaa	atgaagtgtt	aaatcaatct	aaagtatata	tgagtaaact	tggtctgaca	7320
gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctat	cgttcatcca	7380

tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	ccatctggcc	7440
ccagtgtctgc	aatgataccg	cgagacccac	gtccaccggc	tccagattta	tcagcaataa	7500
accagccagc	cggaagggcc	gagcgagaa	gtggtcctgc	aactttatcc	gcctccatcc	7560
agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	gccagttaat	agtttgcgca	7620
acgttgttgg	cattgctaca	ggcatcgtgg	tgtcacgctc	gtcgtttggt	atggcttcac	7680
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaag	7740
cggttagctc	cttcggtcct	ccgatcgttg	tcagaagtaa	gttggccgca	gtgttatcac	7800
tcatggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	agatgctttt	7860
ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	ccgcgcccgg	cgaccgagtt	7920
gctcttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	7980
tcatcattgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttgagat	8040
ccagttcgat	gtaaccctact	cgtgcaccca	actgatcttc	agcatctttt	actttcacca	8100
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaggga	ataaggggcg	8160
cacggaaatg	ttgaatactc	atactcttcc	tttttcaata	ttattgaagc	atztatcagg	8220
gttattgtct	catgagcgga	tacatatttg	aatgtattta	gaaaaataaa	caaatagggg	8280
ttccgcgcac	atttccccga	aaagtgccac	ctgtatgcgg	tgtgaaatac	cgcacagatg	8340
cgtaaggaga	aaataccgca	tcaggcgaaa	ttgtaaactg	taatatattt	ttaaaattcg	8400
cgttaaatac	ttgttaaata	agctcatttt	ttaaccaata	ggccgaaatc	ggcaaaatcc	8460
cttataaatc	aaaagaatag	accgagatag	ggttgagtgt	tgttccagtt	tggaacaaga	8520
gtccactatt	aaagaacgtg	gactccaacg	tcaaaggcg	aaaaaccgtc	tatcagggcg	8580
atggcccaact	acgtgaacca	tcacccaaat	caagtttttt	gcggtcgagg	tgccgtaaa	8640
ctctaaatcg	gaaccctaaa	gggagccccc	gatttagagc	ttgacgggga	aagccggcga	8700
acgtggcgag	aaagggaagg	aagaaagcga	aaggagcggg	cgctagggcg	ctggcaagtg	8760
tagcgggtcac	gctgcgcgta	accaccacac	ccgccgcgct	ttaa		8803

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057474 A3

- (51) International Patent Classification⁷: C12P 13/02, C12N 15/03
- (74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (21) International Application Number: PCT/US02/01842
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 19 January 2002 (19.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/262,995 19 January 2001 (19.01.2001) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): BASF AKTIENGESELLSCHAFT [DE/DE]; 67056 Ludwigshafen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HERMANN, Theron [US/US]; 18 Chilhowie Drive, Kinnelon, NJ 07405 (US). PATTERSON, Thomas, A. [US/US]; 89 Church Street, Attleboro, MA 02760 (US). PERO, Janice, G. [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US). YOCUM, Rogers, R. [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). BALDENIUS, Kai-Uwe [DE/DE]; Kneippstrasse 16, 67063 Ludwigshafen (DE). BECK, Christine [DE/DE]; Max-Joseph-Strasse 35, 68167 Mannheim (DE).
- Published:
— with international search report
- (88) Date of publication of the international search report:
2 October 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/057474 A3

(54) Title: PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

(57) Abstract: The present invention features improved methods for producing pantoate and pantothenate utilizing microorganisms having modified pantothenate biosynthetic enzyme activities. In particular, the invention features methods for reducing byproduct formation and increasing yields and purity of desired product. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

INTERNATIONAL SEARCH REPORT

PCT/US 02/01842

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P13/02 C12N15/03

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 006 189 A (DEGUSSA ;KERNFORSCHUNGSANLAGE JUELICH (DE)) 7 June 2000 (2000-06-07) the whole document ---	1-19, 28-55
X	US 6 171 845 B1 (ELISCHWESKI FRANK ET AL) 9 January 2001 (2001-01-09) the whole document ---	1-19, 28-55
P,X	WO 01 21772 A (OMNIGENE BIOPRODUCTS) 29 March 2001 (2001-03-29) cited in the application the whole document ---	1-55
E	WO 02 061108 A (PERO JANICE G ;YOCUM ROGER R (US); HERMANN THERON (US); OMNIGENE B) 8 August 2002 (2002-08-08) the whole document ---	1-55
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

10 April 2003

Date of mailing of the international search report

24/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Piret, B

INTERNATIONAL SEARCH REPORT

PCT/US 02/01842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PRIMERANO D A ET AL: "ROLE OF ACETOHYDROXY ACID ISOMEROREDUCTASE IN BIOSYNTHESIS OF PANTOTHENIC ACID IN SALMONELLA TYPHIMURIUM"</p> <p>JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US,</p> <p>vol. 153, no. 1, 1983, pages 259-269, XP000611416</p> <p>ISSN: 0021-9193</p> <p>---</p>	
A	<p>KUNST F ET AL: "THE COMPLETE GENOME SEQUENCE OF THE GRAM-POSITIVE BACTERIUM BACILLUS SUBTILIS"</p> <p>NATURE, MACMILLAN JOURNALS LTD. LONDON, GB,</p> <p>vol. 390, 20 November 1997 (1997-11-20), pages 249-266, XP002937517</p> <p>ISSN: 0028-0836</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

PCT/US 02/01842

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1006189	A	07-06-2000	DE 19855312 A1	08-06-2000
			BR 9905783 A	24-04-2001
			CN 1256313 A	14-06-2000
			EP 1006189 A2	07-06-2000
			HU 9904448 A2	28-11-2000
			JP 2000166580 A	20-06-2000
			KR 2000047833 A	25-07-2000
			SK 164099 A3	11-07-2000
			US 6177264 B1	23-01-2001
			ZA 9907407 A	07-06-2000
US 6171845	B1	09-01-2001	DE 19846499 A1	20-04-2000
			AU 5357099 A	13-04-2000
			BR 9904449 A	14-11-2000
			CN 1254758 A	31-05-2000
			EP 1001027 A2	17-05-2000
			HU 9903458 A2	28-12-2000
			JP 2000116387 A	25-04-2000
			KR 2000028952 A	25-05-2000
			PL 335926 A1	10-04-2000
			SK 137799 A3	12-09-2000
			ZA 9906367 A	13-04-2000
WO 0121772	A	29-03-2001	AU 7708700 A	24-04-2001
			BR 0014115 A	21-05-2002
			EP 1214420 A2	19-06-2002
			HU 0202705 A2	28-12-2002
			NO 20021382 A	16-05-2002
			WO 0121772 A2	29-03-2001
			AU 8527601 A	04-03-2002
			WO 0216601 A2	28-02-2002
			US 2002168681 A1	14-11-2002
WO 02061108	A	08-08-2002	WO 02061108 A2	08-08-2002
			WO 02057476 A2	25-07-2002
			WO 02057474 A2	25-07-2002